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 In animals, disease progression can be influenced by genetics, environment, 
management practices, and the type of pathogen. Infection with porcine circovirus 2 
(PCV2) causes development of diseases known as porcine circovirus 2-associated 
diseases (PCVAD), for which there is currently no treatment. In Trial 1, weanling 
unvaccinated barrows and gilts (n = 229) from two genetic lines were bled at d14, 49, and 
at necropsy to assess disease progression from natural infection using antibodies (ELISA) 
and viral copy counts (quantitative PCR). Virus was isolated from infected pigs and 
sequenced to determine the strain responsible for infection. At d49, 113 animals had 
active infection. At necropsy, clinical signs of infection were found in 16% of the pigs. In 
Trial 2, barrows from two genetic lines (n = 81) were infected with an inoculate known to 
cause PCVAD. Blood and weights were collected before infection and at d7, 14, 21, and 
28 to characterize response. Pigs were classified as early responders (n = 33), late 
responders (n = 40), and non-responders (n = 7) based on IgM levels. Other traits were 
fitted to a mixed model with effects of group and line, and random effect of litter. Means 
of viral load throughout the 28-day period differed (P < 0.01) between early and late 
 
responders and non-responders. Viremia differed among groups (P < 0.01) at d14, 21, 
and 28. Viremia of non-responders was 18% less than early and late responders at d14, 
and 22% less at d21. Non-responders tended to have greater growth rate than the other 
groups. Variation in immune response can be utilized in genomics studies to identify 
genetic markers for disease resistance that can be used to select for disease resistance.  
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 1 
 INTRODUCTION 
 
 
 Porcine circoviruses (PCV) are members of the genus Circovirus and the family 
Circoviridae. The most notable of the porcine circoviruses is porcine circovirus type 2, 
PCV2, which has been associated with several disease syndromes since its initial 
classification in 1996. The genome contains single-stranded, non-enveloped, circular 
DNA molecules, and is 1768 nucleotides in size (Gillespie et al., 2009). Two major open-
reading frames have been identified; open-reading frame 1 encodes for proteins involved 
in viral replication, and open-reading frame 2 encodes the capsid protein surrounding the 
virus (Carman et al., 2008).   
 Porcine circovirus 2 is further classified into two categories, a and b, with a first 
detected in North America, and b first detected in Europe (Takahagi et al., 2009). It has 
been demonstrated in field studies and previous research that PCV2a is the less virulent 
strain of the virus. The other category, PCV2b, is most usually defined as the etiological 
agent of PCVAD, porcine circovirus associated diseases.  
 The most common characteristics in all PCV2 infections are signs of lymphoid 
depletion and lymphopenia in circulating blood. The virus is able to attack the immune 
system by affecting both macrophages and dendritic cells. Although PCV2 is observable 
in these cells, it has been suggested that they are not the sites of viral replication. Several 
studies have indicated that dendritic cells may be the source of transportation for viral 
cells. However, not much is known about the pathogenesis of the PCV2 virus (Opriessnig 
et al., 2007). 
 Porcine circovirus associated diseases affect several biological systems in the pig. 
First, the porcine respiratory disease complex (PRDC) has been linked to infection with 
 2 
PCV2. Also, PCV2 can cause gastrointestinal complications in the form of PCV2-
associated enteritis, reproductive issues in the form of PCV2-associated reproductive 
failure, and a vascular disease known as porcine dermatitis and nephropathy syndrome. 
The most notable disease syndrome caused by PCV2 infection is known as post-weaning 
multisystemic wasting syndrome (PMWS). This disease state causes a wasting condition 
in which pigs are unable to put on adequate weight and exhibit depletion in lymphocytes 
leading to an inability to fight off other infections.  
 The development of PCVAD is reliant on many factors. Many strains of PCV2b 
have been isolated and sequenced, and a difference in virulence among the strains can 
affect the severity of the virus and thus the severity of disease conditions. There is also a 
genetic effect, in which certain breeds are more susceptible to the disease than others. 
Studies have indicated a vast difference in the development of clinical signs in pigs of 
varying breeds including Large White, Pietrain, Duroc, and Landrace. Co-infections with 
other viruses or bacteria such as Mycoplasma hyopneumoniae, porcine parvovirus, 
porcine reproductive and respiratory disease, and swine influenza can all affect disease 
progression of PCV2. Host factors, such as the amount of maternal antibodies acquired 
from colostrum in the first hours of life, can have an effect on the development of PCV2 
associated diseases. 
 A vaccination protocol for PCV2 exists. Four commercially available vaccines are 
on the market, with the first being approved for use in the United States in 2007. The 
vaccines vary in dosing, antigen content, and the age of pig for which they are licensed. 
Vaccinations have been proven successful in lowering mortality rates in both field studies 
and farm applications (Takahagi et al., 2009). However, every pig in the herd must be 
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vaccinated in order to prevent an outbreak, even though many pigs contract the virus and 
show no clinical signs. The use of selection to eliminate the need for vaccines against 
PCV2 would be ideal to save the swine industry millions in vaccination costs yearly. 
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1.1 LITERATURE REVIEW 
 
 
Characteristics of PCV2 
 Porcine Circovirus (PCV) emerged in 1974, initially as a contaminant of the 
porcine kidney cell line PK-15 (Grau-Roma et al., 2010). This PK-15 PCV isolate did not 
elicit clinical disease in pigs in experimental challenges.  Allan et al., 1995, demonstrated 
that infecting pigs with PCV that were Cesarean-delivered and colostrum-deprived 
resulted in replication of the virus, but no lesions or disease state was induced (Sorden, 
2000).  
In 1991, post-weaning multisystemic wasting syndrome, PMWS, emerged and 
was known to be associated with a circovirus (Allan and Ellis, 2000). Sequence analysis 
comparison of the two virus strains showed that the sequence from PCV and the one 
causing PMWS had 75-76% nucleotide sequence identity. This lead to the discovery of 
another type of circovirus; the non-pathogenic virus became PCV1 and the new virus 
became PCV2 (Opriessnig et al., 2006a). In addition to the two types, PCV2 can be 
broken down into two categories: PCV2a, detected in North America, and PCV2b, 
detected in Europe (Takahagi et al., 2009). According to Grau-Roma et al. (2010), studies 
show that PCV2b is more prevalent in natural infections of herds. Therefore, PCV2b may 
have higher virulence than PCV2a.   
The porcine circoviruses are members of the genus Circovirus of the family 
Circoviridae. Other members of the genus Circovirus include beak and feather disease 
virus, canary circovirus, goose circovirus, and pigeon circovirus (Opriessnig et al., 2007). 
The Circoviridae family genomes contain single stranded, non-enveloped DNA 
molecules that are circular in shape and range in size from 1.8 to 2.3 kilobases 
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(Opriessnig et al., 2007). Because the DNA molecules are non-enveloped, the virus is 
resistant to many disinfectants, such as those with alcohol, chlorhexidine, iodine, and 
phenol bases (Grau-Roma et al., 2010). The virion DNA is single-stranded and negative 
sense, with 1,800 bases and six open reading frames (Chae, 2005). Porcine circovirus was 
discovered to be the smallest virus capable of replicating independently in mammalian 
cells (Kim et al., 2004b).  
 Porcine circoviruses can be divided into type 1 or 2. Type 1 is generally regarded 
as non-pathogenic, while type 2 is considered pathogenic. Type 1 and 2 share about 75 
percent nucleotide sequence identity (Opriessnig et al., 2006b). Because Type 1 has not 
been shown to induce a disease in swine, research has been more focused on Type 2 as 
the cause of several diseases (Finsterbusch and Mankertz, 2009). 
 PCV2 is an icosahedral, non-enveloped virion (Takahagi et al., 2009). Isolates of 
PCV2 have genomes ranging from 1767 to 1768 base pairs (Opriessnig et al., 2006b). 
The virion is about 17 nm in diameter (Takahagi et al., 2009). There are two major open 
reading frames that are associated with PCV2. The first, open reading frame 1 (ORF1), 
enables viral replication by encoding for replication proteins. Open reading frame 2 
(ORF2) encodes the capsid protein to surround the virus (Carman et al., 2008).  
 Infection with PCV2 is complex in that infected pigs can remain asymptomatic. 
Pigs that are highly viremic with PCV2 DNA may develop diseases associated with 
PCV2 infection. These diseases have been classified as Porcine Circovirus 2 Associated 
Diseases (PCVAD), and include PMWS, PDNS, PCV2-associated reproductive failure, 
PCV2-associated enteritis, and porcine respiratory disease complex (PRDC).  
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Pathogenesis 
 The development and step-by-step events leading to infection and replication of 
PCV2 are somewhat unclear to scientists. It seems that the disease consistently causes 
lymphoid depletion and low levels of lymphocytes in peripheral blood. Reduction of 
lymphocytes in infected pigs can be attributed to several factors, including reduced 
production in the bone marrow, reduced proliferation in secondary lymphoid tissues, or 
increased loss of lymphocytes in areas such as the bone marrow, peripheral blood, or 
secondary lymphoid tissues (Opriessnig et al., 2007).      
 Dendritic cells have a distinctive ability to start an immune response and control 
homeostasis within lymphoctyes. Because they are highly networked in many locations 
such as the skin, mucosal surfaces, and circulating in blood, dendritic cells are able to 
deal with viruses rapidly once they have been encountered. This cell type is responsible 
for encapsulating antigens and travelling to lymph nodes and organs to activate T cells 
for an increased immune response (Vincent et al., 2003). In the study carried out by 
Vincent and others in 2003, it was determined that both bone-marrow-derived and 
monocyte-derived dendritic cells are affected by PCV2 infection. In the Opriessnig et al. 
(2007) review, it was further described from Vincent’s study that replication in dendritic 
cells could not be proven. However, PCV2 was able to persist in the cells without 
undergoing induction of apoptosis. It was suggested that dendritic cells might be utilized 
as vehicles for transportation because of their migratory ability. 
 Porcine circovirus 2 manifests itself in both macrophages and dendritic cells, but 
studies using in vitro models have found that monocytes may not be the site of PCV2 
replication (Opriessnig et al., 2007). The review by Opriessnig et al., 2007, describes in 
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detail the work of Gilpin and others, 2003, in which macrophages and monocytes were 
tested for their facilitation of PCV2 replication. In that study, replication was not 
observed, but neither was degradation in the cytoplasm of both monocytes and 
macrophages.  
 Fenaux and others in 2002 developed an infectious clone of PCV2 to help 
understand the role of PCV2 in systemic diseases. They infected specific pathogen-free 
pigs with cloned genomic PCV2 DNA by direct injection into the livers and superficial 
iliac lymph nodes. After 35 days post infection (d.p.i.), PCV2 antigen was detected in a 
variety of tissues and organs in the pigs, and lesions were found on both the lungs and 
lymph nodes. This study was groundbreaking because it illustrated that in vivo 
transfection could be used to study the relationships of PCV2 genes to assess their roles 
in both virus replication and pathogenesis.  
 Not clearly understood is the reason that some pigs will develop clinical signs of 
the disease upon infection, whereas other pigs will not manifest any signs. Porcine 
circovirus 2b has been shown to be influenced by several factors that can either enhance 
or prevent spread of the virus. These aspects, as explained by Opriessnig and others in the 
2007 review, are: virus-dependent factors, host-dependent factors, effect of coinfections, 
and effect of immune modulation. 
 
Influential Factors - Virulence 
 Virus dependent factors can have an effect on the pathogenicity and transmission 
of PCV2. Virulence fluctuates from strain to strain; one isolate can infect a whole herd of 
pigs, whereas another isolate can have no clinical manifestations. It has been reported 
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that most herds in the United States are infected with PCV2 (Allan and Ellis, 2000; 
Opriessnig et al., 2006a), but many herds do not exhibit PCV2-associated diseases, 
whereas other farms report high occurrence and high mortality numbers (Larochelle et 
al., 2003; Opriessnig et al., 2006a).  
 A study by Opriessnig and others (2006b) compared two isolates, PCV2-40895 
and PCV2-4838, both of which were defined as PCV2a. The isolate PCV2-40895 was 
taken from a pig diagnosed with post-weaning multisystemic wasting syndrome, a PCV-
associated disease. The pig had lymphoid depletion, histiocytic replacement of lymphoid 
follicles, and high PCV2 antigen counts. The second isolate, 4838, was taken from a pig 
from an Iowa farm that suffered from respiratory disease. Streptococcus suis, Pasteruella 
multiocide, and Mycoplasma hyopneumoniae were isolated from this pig. The pig did not 
show signs of PCV2-associated lymphoid lesions, but did test positive for PCV2 DNA.  
 Viruses from both animals were sequenced and the genomes for both were found 
to be 1768 base pairs. In open reading frame (ORF) 1, the two isolates had 98.9 percent 
sequence identity and had only 19 sequence differences. The sequence differences 
resulted in five nucleotide differences; two caused amino acid shifts. The ORF 2 capsid 
gene of the two isolates shared 98 percent nucleotide identity and 96.1 percent amino 
acid identity. This study demonstrated that two strains that are genetically somewhat 
similar could have a variety of effects on the host.  
 Following this study, Opriessnig and others in 2008 conducted a study in which 
the same strains, now referred to as ISU-40895 and ISU-4838, were used, as well as NC-
16845 and Can-17639. The strain NC-16845 was isolated from a group of pigs showing a 
history of severe respiratory disease, specifically lymphadenitis and bronchointerstitial 
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pneumonia. The strain Can-17639 was taken from a group of pigs demonstrating wasting, 
coughing, and bronchointerstitial pneumonia. While ISU-40895 and ISU-4838 were 
classified as PCV2a, NC-16845 and Can-17639 were classified as PCV2b. One hundred 
and thirteen pigs were used for the study and were inoculated with one of the four virus 
isolates. Upon necropsy and sequencing, it was determined that the four genome 
sequences shared 95.7% identity. The two PCV2b isolates alone shared 99.9% nucleotide 
sequence identity. However, because none of the isolates generated clinical symptoms, 
and because there were no differences in macroscopic lesions between groups, the results 
of the study only shed light on the differences between the strains, not their effects.  
 Another study published by Grierson and others (2004) looked at 10 isolates of 
PCV2 in the Netherlands from four farms with clinical signs of PMWS and six farms 
without. The virus was isolated and sequenced in each case, and the sequences were 
aligned. It was found that the 10 strains of PCV2 had 95.6 to 100% sequence identity. 
However, because the strains were causing symptoms on some of the farms and no 
symptoms on the others, and they were genetically very similar or exactly similar, it was 
concluded that small differences in nucleotide sequences of PCV2 do not fully elucidate 
why some pigs show symptoms and others do not. 
 Last, de Boisseson and others in 2004 looked at 23 herds in the region of Brittany 
in France. The virus from each herd was isolated and sequenced. It was noted that 10 of 
the isolates did not cause signs of PMWS and were recorded as PMWS – (negative). 
Thirteen of the strains did cause PMWS and were known as PMWS + (positive) cases. It 
was found that there was a broader nucleotide diversity (94.6 to 99.9% sequence identity) 
in the PMWS – pigs as compared to a nucleotide diversity of 99.5 to 99.9% in the  
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PMWS + pigs. Also, two clusters were identified that the sequences of strains fit clearly 
into. Interestingly, Cluster I contained the strains from France, the United Kingdom, and 
The Netherlands exclusively, while in Cluster II fit the strains from North America, Asia, 
Germany, and Spain. This study concluded that different strains of PCV2 have variable 
effects on the development of PMWS—some infected pigs showed signs of the disease 
and others did not.  
 
Influential Factors - Breed Differences 
Host susceptibility has been shown to affect disease progression of PCV2. 
Previous research has demonstrated that every pig breed around the world is susceptible 
to infection with PCV2. However, the degree of susceptibility appears to vary across 
breeds.  
 In a study by Opriessnig and others (2006a), three breeds were tested to determine 
whether there is a difference in susceptibility to PCV2 infection and development of 
PCV2 associated diseases. The three groups of purebreds used were Duroc, Landrace, 
and Large White because they represent the genetic make-up of a large percentage of 
commercial swine herds in the United States. Pigs were inoculated with a single strain of 
PCV2 (ISU-40895) and then scored for clinical symptoms, tested serologically, and 
underwent histological examination and immunohistochemical analysis. It was found that 
Landrace pigs had significantly more severe lymphoid depletion in the tonsillar region as 
well as in the lymph node pool. Also, microscopic lesions that were characteristic of 
PMWS developed in 15.8% of the Landrace pigs, whereas none of the Duroc and Large 
White pigs developed these lesions. These three Landrace pigs also experienced moderate 
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to severe granulomatous enteritis, as well as moderate lymphohistiocytic inflammation in 
the kidney and thymus. There were no significant differences in the susceptibility to 
PCV2, as measured by viremia, genomic DNA copy counts, and anti-PCV2 antibody 
levels. Nevertheless, there was a difference in the amount of lesions consistent with 
PMWS that developed in the Landrace pigs versus the Duroc and Large White pigs. So 
while Landrace pigs are no more susceptible to contracting the virus, they may have a 
higher vulnerability for PCVAD.  
 Opriessnig and others (2009a) continued breed susceptibility research by 
conducting a study using 39 Landrace and 39 Pietrain pigs. The pigs were inoculated 
with the same strain as the one used in the previous study (ISU-40895), were clinically 
evaluated, slaughtered, and underwent histopathology, lymphoid lesion scoring, and 
immunohistochemistry. For the Pietrain pigs, 34.6% had mild depletion of lymph node 
follicles. However, 30.7% of Landrace pigs had moderate to severe lymphoid depletion. 
In addition, Landrace pigs experienced a variety of lesions that were scored as mild  
(n = 6), moderate (n = 5), and severe (n = 1), whereas the Pietrain pigs had only mild 
lesions (n = 9). The study results imply that the Landrace breed demonstrates a higher 
susceptibility to the development of lesions associated with PCV2 infection. It also 
indicates that Pietrain pigs have the propensity for becoming infected with the virus and 
not developing histopathological symptoms.  
 A study by Rose and others in 2005 used 540 pigs that were born to Pietrain or 
random boars and random sows known as X and Y. The study consisted of clinical 
evaluations and serology. It was found that the average rate of occurrence of PMWS 
overall was 18%. In addition, the morbidity rate in the X-derived pigs was 17.3%, while 
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the morbidity rate in Pietrain pigs was 16.3%. This study demonstrated that Pietrain pigs 
might have some genetic capability to stop the development of PCVAD, although further 
testing is needed to confirm this finding. 
 
Influential Factors - Maternally Derived Antibodies 
 Sows have the ability to pass on immunity to their piglets through colostrum 
secreted shortly after birth. Passively acquired antibodies can bolster the immune 
system’s ability to ward off viruses (McKeown et al., 2005).   
 McKeown and others (2005) conducted a study to determine the role of 
maternally-derived antibodies in the prevention of PCV2 infection. The study utilized 
106 piglets that were separated based on antibody titers and infected with a PCV2 
inoculate. Piglets in group A were considered negative for maternal antibodies, group B 
had low antibodies, and groups C and D had high antibody levels. Groups A, B, and C 
were infected at d0 and d42. Group D was not infected with the virus until d42. The 
piglets in group A experienced seroconversion by 42 days post infection (d.p.i.), 
indicating presence of infection. The low maternal antibodies in group B had waned by 
14 d.p.i., and by 42 d.p.i., four of the five piglets had PCV2 DNA. For group C, the high 
antibody pigs, only two of the eight piglets had PCV2 viremia by 42 d.p.i. In group D, 
who were inoculated later than the other groups, all five pigs became infected with PCV2 
after infection at d42, when the initial maternal antibodies had waned.  
 At the time of second challenge for groups A, B, and C, at d 42, all but group C 
were negative for maternal antibodies, and only two group C pigs became viremic. The 
results of this study indicated that piglets exposed to PCV2 with little or no maternal 
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antibodies did not have protection against the virus, and therefore exhibited 
seroconversion and became viremic.  
 In a study described by Calsamiglia et al. (2007), 15 sows from seven farms were 
chosen and after farrowing, the piglets were followed up to seven months of age. 
Pathological exams were performed to check for signs of PMWS. Forty of the 63 piglets 
that lived to the seven-month mark and sent to necropsy (63.5%) were diagnosed as 
having PMWS. However, 36 out of 38 (94.7%) sows that had piglets live were tested and 
found PCV2 negative. Thirty-two out of the 38 (84.2%) had antibody titers in the 
medium to high range. In the group of sows that had piglets die before the seven-month 
study was finished, only 2 of 7 (28.6%) had medium to high antibody titers. It was 
observed that increasing maternal immunity and decreasing sow infection status could 
lessen the propensity for PWMS.  
 Opriessnig and others (2004a) designed an experiment where the objective was to 
deliver piglets negative for PCV2 from sows positive for PCV2. Among other 
characteristics, sow herd antibody profiles, the transfer of passive antibodies, and 
maternal antibody decay were measured. Viremic conditions were not found in the 
piglets, and the authors suggested that passively-acquired antibodies may be able to stop 
PCV2 replication until the levels of maternal antibodies decrease. At this time, piglets 
would be able to develop clinical symptoms of PCV2 and could experience progression 
to PCVAD. 
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Influential Factors - Co-infection 
 Porcine circovirus 2 has been found to act as a co-infecting agent in conjunction 
with other viruses and bacteria. According to a review published by Grau-Roma et al. in 
2010, there are at least eight viruses, three mycoplasmas, and three bacterial agents that 
have been found as co-infectors in PMWS cases. These viruses include PRRSV, PPV, 
porcine epidemic diarrhea virus, Aujeszky’s disease virus, Hepatitis E virus, torque teno 
virus (TTV), porcine teschovirus, and swine influenza virus (SIV). The Mycoplasma 
most associated with PCV2 is Mycoplasma hyopneumoniae, although two others, M. 
hyorhinis and M. suis have been noted as PCV2 co-infectors. Several bacteria, including 
Salmonella cholera suis, Escherichia coli, and Haemophilus parasuis, have been found in 
conjunction with PCV2.    
In a field study completed by Pallares et al. in 2001 at the Iowa State Veterinary 
Diagnostic Laboratory, the experimenters reviewed 4,688 tissue submissions for presence 
of PCV2 and PMWS. Thirty-seven percent (1,751) of the tissues tested positive for PCV2 
using immunohistochemistry. Conversely, 484 (10.3%) of the 4,688 samples tested 
positive for PMWS. Most (80%) of the cases used in the study came from Iowa, followed 
by North Carolina, Oklahoma, and Minnesota. Infection with both PCV2 and PRRSV 
was the most common combination, with 164 cases; following that was PCV2 with M. 
hyopneumoniae (92), PCV2 with bacterial septicemia (68), PCV2 with bacterial 
pneumonia (37), and PCV2 with swine influenza. In addition, 77 pigs experienced 
infections of PCV2, PRRSV, and M. hyopneumoniae. Only nine of 4,688 cases showed 
singular infection of only PCV2. Of the 384 cases demonstrating PMWS, 369 ages were 
provided. It was found that PMWS occurred between 8 and 18 weeks in 294 of the 369 
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pigs. PMWS was found most in pigs 10 weeks of age. This age of presentation was 
normally distributed and corresponds with the findings of other reports (Pallares, 2001). 
A study by Krakowka and others (2000) looked at the effects of a dual infection 
of PCV2 and PPV in gnotobiotic pigs. Twenty-six piglets delivered by C-section were 
divided into infection groups, PCV1 alone (n = 3), PCV2 alone (n = 3), PPV alone  
(n = 3), PCV1 and PPV (n = 4), PCV2 and PPV (n = 4), and PCV1 and PCV2 (n = 4). 
Three pigs were kept as controls. Those pigs receiving only one infectious agent 
remained normal, with only a small enlargement of the lymph nodes. The four piglets 
receiving PCV1 and 2 together also remained clinically normal. Pigs inoculated with the 
combination dose of PCV2 and PPV developed acute gross lesions characteristic of 
PMWS. All four pigs developed a jaundice condition as well as subcutaneous edema. 
This caused the need for euthanasia on 30 d.p.i.. Three of the four piglets in this group 
experienced a decrease in thymic size, and three had moderate histological lesions. This 
was vastly different from piglets receiving a single infectious dose. The piglets with PPV 
alone never became viremic. Only half of the PCV1 pigs became viremic. This study 
confirmed that PCV2 is the viral pathogen, because PCV1 was unable to manifest clinical 
symptoms. Also, it was determined that in gnotobiotic piglets, the presence of PCV2 was 
consistent in all PMWS cases, but not enough alone to cause clinical symptoms.    
 Numerous studies have been conducted to understand the importance of PRRSV 
infection in the development of PCVAD. A brief report by Allan and others (2000) 
explained attempts to infect colostrum-deprived piglets with both PCV2 and PRRSV. 
Four pigs were inoculated with PRRSV alone, three with PCV2 alone, and five with an 
equal mixture of PCV2 and PRRSV. In the pigs infected with one virus, no clinical 
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disease or gross lesions developed. One pig with dual infection suffered from enlarged 
lymph nodes, and thymic atrophy was observed in another dual infection pig. Also, as is 
common with PMWS, lymphoid, liver, renal, and vascular lesion were seen in four of the 
five PRRSV/PCV2 pigs. Because disease developed in only those pigs dually-infected, it 
was suggested that infection with PRRSV could enhance the replication of PCV2 and 
thus lead to clinical symptoms of PCVAD.  
 Another study consisting of PRRSV and PCV2 was conducted by Harms and 
others in 2001. They utilized 59 piglets from 10 sows and placed them into four treatment 
groups: controls (n = 10), PCV2 (n = 19), PRRSV (n = 13), and PCV2/PRRSV (n = 17). 
No respiratory symptoms were noticed in the control pigs. The PCV2 pigs had mild 
clinical respiratory disease. One pig from the PCV2 group died of severe exudative 
epidermitis and three died from hemorrhagic gastric ulcers before the study was 
completed. In addition, two pigs from the PCV2 group were euthanized early due to 
severe depression, lethargy, and jaundice.  
 The PRRSV pigs developed acute respiratory problems after the seventh day post 
infection that were significantly worse than the PCV2 and control pigs; however, no pigs 
died or were euthanized from this group. The PCV2/PRRSV pigs had similar respiratory 
problems to the PRRSV pigs. Between 10 and 20 d.p.i., 10 of 11 pigs contracted acute 
dyspnea and depression. Four of these pigs died early, and six were euthanized for the 
sake of animal welfare. The remaining PCV2/PRRSV pig died at 20 d.p.i.. The 
PCV2/PRRSV pigs had more severe and recurrent hepatic lesions than PCV2 pigs, as 
well as more severe lymphoid depletion. In addition, the dually infected pigs all 
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experienced necrotizing hepatitis and interstitial pneumonia. It was concluded that 
PRRSV could enhance the progression of PCV2 in the pig model.  
 A study by Opriessnig and others (2004b) incorporated 67 crossbred piglets into 
four groups. Seventeen pigs received no inoculations, whereas 17 received Mycoplasma 
hyopneumoniae alone, 16 received PCV2 alone, and 17 received an infectious dose 
containing both M. hyopneumoniae and PCV2. Single M. hyopneumoniae infections 
exhibited mild to moderate respiratory disease whereas in dual M. hyopneumoniae/PCV2 
infections it was mild to severe. The severity of M. hyopneumoniae-associated lesions 
were similar between single and dual infections. Pigs in the PCV2 alone group and the 
dual infection group experienced a two to three times normal size enlargement of lymph 
nodes. Pigs in the M. hyopneumoniae group did not illustrate this condition. All treatment 
pigs developed interstitial pneumonia, and four of the 17 dually infected pigs showed 
signs and lesions pertaining to PMWS. None of the PCV2 alone group exhibited signs of 
PMWS. The authors concluded that M. hyopneumoniae could strengthen the effects of 
PCV2 and lead to more severe clinical disease.   
 Last, Pogranichniy et al. (2002) conducted a field-based case control study in 
which pigs from four to 16 weeks of age showing signs of PMWS were observed. Thirty-
one infected pigs and 56 controls were utilized and tested for PCV2, PRRSV, PPV, 
porcine enterovirus, SIV, porcine respiratory coronavirus (PRCV), transmissible 
gastroenteritis virus (TGEV), porcine endogenous retrovirus (PERV), porcine 
lymphotropic herpesvirus (PLHV), and bovine viral diarrhea virus (BVDV). All animals 
tested positive for PERV, which is known as omnipresent in swine. Porcine circovirus 2 
was present in 29 of 31 (94%) PMWS pigs, as well as in 35 of 56 (63%) controls. In 
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addition, PRRSV was detected in 42% of the PMWS animals and 20% of the controls. 
After statistical analysis, it was determined that the odds ratio for the association between 
PCV2 and PMWS was 9.3, meaning that a pig with PCV2 is 9.3 times more likely to 
develop PMWS as compared to pigs not viremic for PCV2. The analysis also indicated 
that an animal is 31.2 times more likely to develop PMWS if infected by both PCV2 and 
PRRSV.  
All of these studies currently lead to no concrete conclusions about whether a 
single pathogen perpetuates the infectious nature of PCV2. According to a review by 
Opriessnig and others from 2007, it appears that several infectious agents of varying 
pathogenicity play a role in the development and progression of PCVAD.  
 
Transmission 
Porcine circovirus 2 can be transmitted both horizontally and vertically. The high 
occurrence of PCV2 viral DNA in herds across the world reaffirm the fact that PCV2 is 
effective in terms of transmission (Kristensen et al., 2009). Horizontal transmission 
occurs when infected and non-infected pigs are mixed together (Grau-Roma et al., 2010). 
One study indicated that pigs kept in the same pen with direct contact were able to 
transmit the disease to other pigs more efficiently than pigs in separate pens (Andraud et 
al., 2008). The most common route of infection appears to be intra-nasally, although 
PCV2 can be shed in tonsillar, bronchial, and ocular secretions. Feces, saliva, milk, and 
semen have also been shown to contain PCV2 DNA and therefore could be modes of 
transmission for PCV2 (Krakowka et al., 2000).  
 19 
In a study performed by Yang and others (2003), fecal and intestinal samples 
were obtained from 97 piglets, 63 with signs of enteric disease and 34 piglets that had no 
signs of gastrointestinal problems. Of the 63 piglets with enteric disease, 18 tested 
positive via PCR for porcine circovirus. Because PCV2 DNA was present in 14 intestinal 
samples and four fecal samples, it becomes evident that PCV2 can be shed in feces and 
therefore can be transmitted in fecal matter.    
The possible existence of a respiratory route of infection was demonstrated by 
Magar and others in 2000, when they found that the virus is able to infect the 
nasopharynx and tonsils. From there the virus was able to spread throughout the body by 
way of blood or lymph (as reported in a review by Dupont et al., 2009).  
Indirect infection, when pigs are kept in separate pens but can still spread the 
disease, occurs as well. Kristensen and others (2009) conducted a study with 12 herds of 
pigs where eight herds had signs of PMWS and four did not. In some cases, the pigs were 
mixed inside the pens; in other cases, the non-PMWS pigs were placed in pens next to 
PMWS-pigs; additionally, some affected pigs were kept in pens across the aisle from pigs 
not affected by PMWS. When the pigs were mixed within the pens, 10 of 18 with direct 
contact began to illicit signs of PMWS, while three of 18 in neighboring pens and one of 
18 across the aisle also showed signs. This study concluded that direct and indirect 
contact may induce clinical signs of PMWS.  
Vertical transmission, from dam or sire to piglet, has been proven by several 
studies. Trans-placental infection can occur after intra-nasal infection of pregnant sows 
before farrowing (Ha et al., 2008). PCV2 was found in both pigs born alive and pigs that 
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were aborted. Numerous studies have been conducted to find whether semen or 
colostrum containing PCV2 DNA can be infectious to piglets.  
Madson and others in 2009 implemented a study to attempt to induce infection in 
PCV2-free sows by artificial insemination with PCV2-laced semen. Nine specific 
pathogen-free sows underwent estrus synchronization and insemination using a dose of 
semen mixed with three mL of either PCV2a or PCV2b. In the three sows inseminated 
with semen and PCV2a, no piglets were born live, stillborn, or mummified. The sows 
failed to maintain any pregnancy to gestation. In the three sows inseminated with semen 
and PCV2b, 35 piglets were delivered; however, only eight were born alive, two were 
stillborn, and 25 were mummified. Of the pigs coming from these dams, only the two 
stillborns acquired lesions, and these were classified as due to chronic myocardial 
dysfunction and cardiac dilatation. The authors concluded that intrauterine infection of 
sows could induce viremia in both the sow and fetuses (Madson et al., 2009). 
Larochelle et al. in 2000 and Schmoll et al. in 2008 indicated that PCV2 can be 
shed in semen. In addition, a study performed by Patterson and others in 2010 sought to 
demonstrate and understand shedding and infection dynamics of PCV2. They used 26 
pigs and inoculated them with the virus in a variety of methods: pooled oral samples 
using intraperitoneal (IP) administration, pooled fecal samples using IP, pooled nasal 
samples using IP, pooled oral samples administered orally, pooled fecal samples 
administered orally, pooled nasal samples administered intranasally (IN), and 
intramuscular (IM) injections to administer the virus. All three sources of IP 
administration resulted in PCV2 viremic conditions and seroconversion to anti-PCV2 
antibodies. Nasal samples administered IN also resulted in PCV2 infection. Fecal 
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samples administered orally resulted in infection in two of four pigs. One of the three 
pigs with the IM injection became viremic. However, the oral samples administered 
orally did not result in viremia for PCV2. The conclusions from the study were that 
PCV2 is shed in large amounts nasally, orally, and in fecal secretions in an experimental 
infection.  
In a study performed by Opriessnig and others, the authors wanted to determine if 
PCV2 was transmissible when fed to other pigs via meat and bone meal. Because PCV2 
has been found in lymphoid tissue and bone marrow (Bolin et at., 2001), as well as in 
heart tissue (Kennedy et al., 2000), it is important to know the relationship between oral 
consumption and PCV2 infection. As found by Allan and others in 1994, PCV1 is stable 
at a pH of 3, and because meats in slaughter houses and packing plants do not typically 
reach a pH that low, it is likely that meat from a PCV2-positive animal could still contain 
an infectious form of the virus through storage and possible use afterward (Opriessnig et 
al., 2009b). 
 The authors collected tissue samples including skeletal muscle, spleen, tonsil, 
lymph nodes, and bone marrow from three pigs previously infected with PCV2. Then, 
they brought in 15 two-week old, colostrum-deprived crossbred piglets and separated 
them into treatments based on the tissues they would consume: skeletal muscle orally, 
bone marrow orally, lymphoid tissues orally, or PCV2 inoculate via a stomach tube. 
Necropsy on the piglets was performed, and the virus from the pigs was isolated and 
sequenced. It was found that consumption of PCV2 positive lymph nodes, bone marrow, 
and skeletal muscle caused viremic conditions after only seven days. All of the pigs in the 
study became PCV2 positive, and microscopic lesions due to lymphocytic depletion and 
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histiocytic replacement of lymph follicles were found in nine of the 15 pigs. It was 
determined that infection can be transmitted through uncooked skeletal muscle, bone 
marrow, and lymphoid tissue by way of oral consumption by PCV2- naïve pigs.  
   
Diseases Caused by PCV2 
Post-weaning Multisystemic Wasting Syndrome 
 Post-weaning multisystemic wasting syndrome, known as PMWS, occurs 
throughout the world (Chae, 2005). This disease was first discovered in 1991 in Canada, 
and affects primarily piglets from five to twelve weeks old (Gagnon et al., 2007). 
Symptoms of the disease include wasting and the inability to gain weight, enlargement of 
the inguinal lymph nodes, jaundice, and lymphocytic depletion (Gagnon et al., 2008). In 
addition, pigs with PMWS experience a decline in immunological function due to a 
marked reduction in circulating lymphocytes (Takahagi et al., 2009). The disease 
manifests itself in 10 to 30% of infected pigs (Darwich et al., 2004). This indicates that 
many pigs have developed a susceptibility to the syndrome, despite infection with PCV2. 
In herds that undergo an acute outbreak, mortality due to PMWS can reach 10%; in herds 
that are endemically affected, mortality totals are lower (Allan and Ellis, 2000).  
 Post-weaning multisystemic wasting syndrome is characterized by lesions that 
involve clusters of globular intracytoplasmic inclusion bodies (Sorden, 2000). Lymphoid 
lesions can be found in almost all tissues of an infected animal, including the tonsils, 
Peyer’s patches, spleen, thymus, and most commonly, lymph nodes (Darwich et al., 
2004). Existence of these lesions is indicative of PMWS; however, these lesions are not 
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always present in an animal suffering from the disease. Therefore, there are several other 
methods to precisely detect PCV2 infection that can lead to PMWS. 
 Post-weaning multisystemic wasting syndrome can manifest itself in a variety of 
symptoms. When an infected animal is sent for necropsy, often it is found that the lungs 
are unable to collapse and are tan in color. The kidneys may have white streaks or spots. 
Pigs with PMWS may also experience enlargement of several lymph nodes, including 
mesenteric, mediastinal, and superficial inguinal (Gillespie et al., 2009). 
 In addition to the presence of lesions and other clinical signs, PMWS can alter 
cytokine expression in infected pigs. The disease causes an over-expression of interleukin 
10 (IL-10) in the thymus, which can lead to thymic depletion as well as atrophy in the 
thymus. Also, PMWS increases the expression of interferon-gamma (IFN-γ) in the tonsils 
(Darwich et al., 2003). In the study Darwich and others published, they used 10 eight-
week old piglets that were showing signs of wasting and respiratory disorder. Three pigs 
had such severe thymic atrophy that their thymus could not be found at necropsy. In the 
other seven pigs, enlargement of the lymph nodes, interstitial pneumonia, and 
lymphoplasmacytic hepatitis were observed. Histological lesions had mild to severe 
lymphocyte depletion. In addition, a marked increase in IL-10 was observed. Interleukin-
10 is responsible for having an anti-inflammatory effect in the body, and also regulates 
natural killer and B-cell growth; thus, an increase in IL-10 indicates the presence of an 
active immune stressor. Another observation from the study was a decrease in IL-2 and 
IL-12 in the spleen, likely due to extensive T-cell damage.  
 Development of PMWS depends on numerous factors. Sows vaccinated against 
PCV2 can protect piglets via passive immunity. Experimental infections by Tomas et al. 
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in 2008 indicated that piglets that did not receive colostrum from sows had a higher 
incidence of PMWS. A study by Calsamiglia et al. in 2007 also demonstrated that piglets 
born to sows with low maternal antibodies had higher mortality rates than piglets born to 
sows with higher antibody titers. In addition, it was found that sows with high PCV2 
viremia had higher piglet mortality rates (Grau-Roma et al., 2010). Also, management 
flaws such as drafts, overcrowding, mixing ages of pigs, and deficient air quality can 
worsen PMWS conditions (Harding and Clark, 1997). Post-weaning multisystemic 
wasting syndrome is known as multifactorial; PCV2 is needed for development of the 
disease, but infection with PCV2 is not necessarily enough to create a clinical condition 
(Calsamiglia et al., 2007). 
 In addition to sow immune status, another factor affecting PMWS development is 
virulence of the infecting strain. Numerous studies have confirmed that PCV2b is the 
strain most common in natural infections with PCV2 (Grau-Roma et al., 2010). Infection 
with PCV2a has been demonstrated to be associated with non-PMWS-affected farms 
(Carman et al., 2008; Grau-Roma et al., 2008). Therefore, the virulence of PCV2a is 
considered to be lower than the virulence of PCV2b. 
 In 2000, Sorden determined a definition of PMWS in which all factors must be 
present for accurate diagnosis. These factors included: presence of clinical symptoms 
such as weight loss, respiratory disease, and wasting; also, the presence of PCV2-
associated lesions, which includes lymphoid depletion or histiocytic replacement of 
follicles in lymphoid tissues; and, the presence of PCV2 antigen or nucleic acid as 
determined by immunohistochemistry (Opriessnig et al., 2007).  
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 In order for a complete and accurate diagnosis of PMWS, formalin-fixed tissue 
samples should be submitted for testing. Portions of the lung work best for diagnosis; 
other suitable tissues include lymphoid tissues (tonsil, thymus, spleen), pancreas, liver, 
and kidney. Fresh samples may be used to rule out the presence of other pathogens, 
including fresh lung, tonsil, and spleen (Sorden, 2000). In their paper, Opriessnig and 
others (2004b) explained a scoring system of seven lymphoid tissues to determine the 
extent of PCV2 infection. These tissues included: superficial inguinal, external iliac, 
mediastinal, tracheobronchial, and mesenteric lymph nodes; spleen; and tonsil. The 
scoring system ranged from zero to three for the categories of lymphoid depletion, 
granulomatous inflammation score, and PCV2-immunohistochemical score. This system 
enabled a subjective but consistent evaluation of tissues affected by infection.  
 There seem to be no herds safe from a PMWS outbreak. The disease can affect 
farrow-to-finish, farrow-to-feeder, off-site nursery, and grower pig operations. It has been 
found in small operations with as little as 50 sows and large operations with as many as 
1200 sows (Harding and Clark, 1997).  
Because many PCV2 cases experienced co-infection, it was postulated that 
various pathogens may use the same mechanism to evade the immune system. Another 
idea is that infection with PCV2 may make pigs more susceptible to the acquisition of 
other pathogens. Infection with PCV2 and other viruses simultaneously, such as porcine 
parvovirus or PRRSV, may perpetuate the effects of the virus (Krakowka et al., 2000). 
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PCV2-associated Enteritis 
Porcine circovirus 2-associated enteritis is not as well reported but can have 
effects on many systems in the body. Pigs with the disease experience diarrhea and 
inflammation of the colon (Kim et al., 2004a). The diarrhea starts out yellowish in color 
and progresses to black. Piglets with PCV2-associated enteritis go through periods of 
decreased weight gains. The disease manifests itself in pigs between 40 and 70d old 
(Chae, 2005).    
Enteritis caused by PCV2 infection is another PCV associated disease. In a 
scenario described by Kim et al. (2004a), 150 Landrace x Large White sows experienced 
an outbreak of PCV2 induced enteritis, where 30% of the piglets developed diarrhea 
symptoms within a 3-week period. The diarrhea was non-responsive to antibiotic 
treatment. Two pigs were selected from the herd and sent to a diagnostic laboratory for 
necropsy. Two more pigs were selected from two other herds and submitted. The pigs 
were euthanized and samples of lung, heart, inguinal lymph node, tonsil, thymus, spleen, 
intestines, liver, kidney, and pancreas were collected, formalin-fixed and paraffin-
embedded. Both small and large intestines were observed for the presence of several viral 
pathogens including PCV2, PPV, PRRSV, and classical swine fever virus (CSFV).  
The pigs consistently demonstrated granulomatous inflammation and lymphoid 
depletion in the Peyer’s patches in both the large and small intestines. Two of the pigs 
suffered from multifocal necrosis and ulceration with fibrin in both the cecum and colon. 
PCV2 was isolated from the lymph nodes of two of the pigs as well. A hybridization 
signal for PCV2 was found in Peyer’s patches from the six pigs. The scientists found, 
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using in situ hybridization, that PCV2 replicated inside the macrophages of the Peyer’s 
patches. 
  Diagnosis criteria of PCV2-associated enteritis include three factors. First, the 
pigs must be suffering from clinical signs of diarrhea; next, the Peyer’s patches must 
contain those lesions consistent with PCV2 infection, but the lesions must NOT be 
present in the lymph nodes; last, lesions in the Peyer’s patches must contain traces of 
PCV2 (Chae, 2005). Diagnosis of the disease can create difficulty because the symptoms 
are similar both clinically and histopathologically to PMWS. The general rule is that if 
lesions are observed in the lymph node, the pig suffers from PMWS; lesions in the 
Peyer’s patches are due to PCV2-associated enteritis (Kim et al., 2004a). 
  
Porcine Respiratory Disease Complex 
 Porcine respiratory disease complex (PRDC) clinically affects pigs around 16 to 
22 weeks of age. Symptoms of the disease include retarded growth, lower feed 
efficiencies, anorexia, cough, and shortness of breath (Kim et al., 2003). An increase in 
mortality due to either single or multiple bacterial infections characterizes the disease 
complex (Chae, 2005). Pneumonia caused by PRDC can be due to both bacterial and 
viral pathogens. Co-infection with PCV2 and other viruses such as PRRSV, swine 
influenza virus, or Mycoplasma hyopneumoniae can intensify the clinical symptoms of 
the disease. For instance, co-infection with PCV2 and porcine parvovirus can produce 
severe lesions (Kim et al., 2003). In addition, experimental evidence suggests that a 
synergy between PCV2 and PRRSV exists (Chae, 2005).  
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 In a study done by Kim and others in 2003, the results illustrated that PCV2 is 
common in pigs that suffer from PRDC. Eighty-five pigs out of 105 showed positive cells 
for PCV2, and 43 of the 85 pigs illustrated co-infection by PCV2, PRRSV, and porcine 
parvovirus (PPV) together. PCV2 was tested by in situ hybridization and consistently 
showed up in the lung lesions, which may mean that PCV2 plays an integral role in the 
development of PRDC (Kim et al., 2003). 
 Porcine respiratory disease complex generally elicits similar symptoms to PMWS. 
However, PRDC usually occurs in older pigs (16 to 22 weeks) as compared to PMWS (8 
to 16 weeks of age). PRDC caused by PCV2 also has several specific histological signs, 
including widespread granulomatous inflammation, multinucleated cells, and 
intracytoplasmic basophilic viral inclusion bodies (Kim et al., 2003). And, PCV2 
consistently causes lesions that demonstrate bronchointerstitial pneumonia with 
peribronchial and peribronchiolar fibrosis (Chae, 2005). 
 Specific criteria have been established in order to diagnose the presence of PCV2 
as the cause of the disease complex. First, there must be the presence of respiratory 
symptoms that do not respond to antibiotic treatments. Next, the pig must have presence 
of pulmonary lesions; also, PCV2 must be present in the lesions. Last, the pig must not 
have the characteristic lesions associated with PMWS. If a pig meets all four criteria, 
PCV2 infection status is the confirmed cause of PRDC (Chae, 2005). 
 
PCV2-associated Reproductive Failure 
 The first report of reproductive failure associated with PCV2 viral DNA surfaced 
in Canada in 1999 (Gillespie et al., 2009). Clinical signs from commercial farms showing 
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infection of PCV2 include higher incidence of abortions, stillbirths, and delivery of fetal 
mummies. Several studies conducted in the early 2000s and reported in a review paper by 
Chae in 2005 indicate that infection of the dam with PCV2 can lead to stillborn near-term 
fetuses and premature piglets.  
Sanchez and others in 2001 determined that PCV2-associated reproduction 
problems can occur throughout all phases of gestation. In addition to infection of the 
dam, it has been demonstrated that PCV2 can be shed in semen of an infected boar. In a 
study by Larochelle and others, four boars were intra-nasally infected with two 
concentrations of PCV2 isolate LHVA-V53. The boars were housed singularly and 
semen was collected 10 times after infection with the virus. In addition, serum samples 
were taken eleven times to test for the presence of PCV2. It was found that the boars all 
recurrently shed PCV2 DNA in their semen. However, it was not determined if the PCV2 
DNA was infectious, and the authors suggested that follow-up studies should be 
conducted to find out if PCV2 shed in the semen could induce infection in sows that were 
either naturally mated to infected boars, or sows that were artificially inseminated with 
infectious semen (Larochelle et al., 2000).  
A study conducted by Kim and others (2004b) used 350 aborted and stillborn 
fetuses from 321 Korean farms to test for the incidence of PCV2, porcine parvovirus, and 
porcine respiratory and reproductive syndrome. Forty-three percent of the piglets that 
underwent reproductive complications tested positive for a least one of the three viruses. 
A total of 35 of the 350 cases tested positive for PCV2 alone. This study promoted the 
idea that PCV2-associated lung lesions are not always present in aborted fetuses. Of 12 
fetuses that were aborted in late gestation, only four exhibited lesions. Two of six 
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stillborn piglets showed lesions as well. The lesions that were present were found in 
varying locations, and were moderately severe. The authors suggested that PCV2 might 
be able to induce reproductive failure in all stages of gestation- early, middle, and late.  
O’Connor et al. (2001) described an outbreak at a 3,000-sow farm where acute 
reproductive losses were experienced. The rate of mummified fetuses rose to almost 15% 
during an 8-week period. In addition, the rate of stillborns and pre-weaning mortality hit 
highs of 8% and 11%, respectively, for that same 8-week period. Piglets from about 40 
litters were sent to necropsy labs, where myocarditis and myocardial necrosis were found. 
Immunohistochemical staining exposed high amounts of PCV2 antigen in myocardial 
lesions in six of the piglets sent to necropsy. Samples from two stillborn piglets and two 
that died soon after birth were submitted and tested for presence of PCV2. The virus was 
found in the hearts of two piglets and in the pooled lung and splenic tissues of the other 
two. This study demonstrated that PCV2 could undergo vertical transmission and infects 
piglets in utero.  
Park and others in 2004 described a study where six pregnant sows were infected 
with a strain of PCV2 isolated from an aborted fetus. Two sows remained uninfected as 
controls. The six infected sows delivered a total of 65 stillborn and 10 liveborn piglets, 
while the control pigs delivered a total of 18 liveborn piglets and no stillborns. Mild 
pneumonia was discovered in 15 of the stillborn, and five of the liveborn  pigs that came 
from infected sows. The authors proposed that PCV2 may be able to infect sows and then 
cross the placenta to infect the piglets. Also, it was demonstrated that PCV2 could 
replicate in fetuses after intra-fetal infection.  
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Porcine Dermatitis and Nephropathy Syndrome 
 Porcine dermatitis and nephropathy syndrome (PDNS) was first discovered in 
1993 in the United Kingdom (Gillespie et al., 2009). The disease syndrome typically 
affects nursery and pigs in the grow-finish stage. However, PDNS has been described in 
finishing pigs and replacement gilts as well (Chae, 2005). Clinical signs of PDNS include 
fever, lethargic behavior, and occasionally loss of appetite (Harding, 2004). In addition to 
these signs, there are often physical manifestations of the disease. Red-purple skin lesions 
may arise in several locations, first starting in the hindquarters, limbs, and abdomen 
(Harding, 2004). These lesions usually progress to scabs containing black centers and are 
located on the rear legs (Gillespie et al., 2009). In addition to visual clinical signs, pigs 
experiencing PDNS often have enlarged, pale kidneys with hemorrhages (Harding, 
2004). Other gross lesions include edema, enlarged lymph nodes, and gastric ulcerations 
(Drolet et. al, 1999). Pigs showing signs of anorexia, weight loss, and skin lesions 
combined usually die quickly; mortality rates in pigs showing a multitude of symptoms 
can reach 20% (Chae, 2005).  
 Porcine dermatitis and nephropathy syndrome is a vascular disease, with the 
primary lesion being a systemic necrotizing vasculitis. Lesions associated with PDNS 
mirror effects of immune complex-mediated disorders that have the ability to commence 
an acute inflammation (Drolet et. al, 1999). 
 The association between PDNS and PCV2 was recognized in 2000 (Opriessnig et 
al., 2007). Although PDNS has commonly been associated with PCV2, it remains unclear 
whether PCV2 is the only virus capable of causing the syndrome. In a study described by 
a review by Gillespie et al. in 2009, Krakowka and others in 2008 found that PDNS was 
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isolated from pigs infected with PRRSV and TTV, but these pigs were PCV2-free. 
Another study by Wellenberg et al. (2004) looked at three pigs from each of 10 Dutch 
herds showing clinical signs of PDNS. The pigs demonstrated fever, lethargy, and were 
affected by skin lesions on several locations of the body. Upon necropsy, the pigs 
exhibited enlarged grey-brown kidneys with white spots on the renal cortex, as well as 
hemorrhagic lymph nodes. It was found that 100% of the pigs contained PCV2 DNA. In 
addition, 33% of the pigs tested positive for PPV and 83% of the pigs tested positive for 
PRRSV. Therefore, although it is known that PDNS is immune-mediated, there has been 
no conclusive evidence that it is related only to PCV2, and that PCV2 is the main cause 
of PDNS.  
 A study by Sipos and others (2005) observed the changes in cytokine levels in 
five pigs known to have PDNS, five pigs known to have PMWS, and five controls. In the 
PDNS pigs, amounts of the cytokines interleukin 1α (IL-1α), interleukin 6 (IL-6), and 
interleukin 10 (IL-10) were significantly greater than in the controls. This was likely due 
to an inflammatory response against the pathogen. In addition, interferon gamma (IFN-γ) 
levels were markedly greater (approximately two-fold) than in controls. The authors 
concluded that this may imply that cytotoxic T cells were important at this stage of 
infection. Lastly, levels of interleukin 2 (IL-2) and interleukin 4 (IL-4) both decreased. 
Since both are found in leukocytes, this could be due to a decrease in the amount of 
overall leukocytes. 
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Diagnosis 
 The presence of clinical signs has thus far been the most straightforward way to 
diagnose PCV2. Characteristics of PWMS, PDNS, and PRDC are generally recognizable 
on farms and in herds. Other associated diseases can be determined by various lab 
procedures. If PCV2 antigen is contained in more than one lymphoid tissue, or a 
lymphoid tissue and an organ system such as the kidney or lung, it is generally regarded 
that PCV2 is present in the body in an infectious capacity. Chronic severe PCV2 is 
demonstrated by severe lesions even in the presence of only limited PCV2 antigen 
content (Gillespie et al., 2009). 
 Immunohistochemistry (IHC) and in situ hybridization (ISH) are methods that 
have been established to recognize PCV2. Both tests use tissues from the animal that 
must first be paraffin-embedded and formalin-fixed. The IHC method utilizes both 
polyclonal antisera and monoclonal antibodies to detect presence of PCV2, and is a rapid 
process with quicker results than ISH. However, a study conducted by McNeilly et al. in 
1999 and discussed in a review by Sorden, 2000, suggested that ISH has the ability to 
detect more positive cells than immunohistochemistry.  
 Both virus isolation and polymerase chain reaction (PCR) can be utilized to 
identify the presence of PCV2. Virus isolation is not as sensitive as immuno-
histochemistry or in situ hybridization, but is useful for the production of vaccines for 
further research. Using PCR, one can successfully detect between PCV1 and PCV2. 
However, it is a method that can easily incur contamination and show false positives. 
Sorden (2000) points out that PCR may be too sensitive a test to determine an accurate 
PMWS diagnosis. And because most pigs experience PCV2 infection at some point in 
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their lives, and PCR can pick up as little as one genomic copy, sensitivity is further an 
issue (Opriessnig et al., 2007).  
 Serology can be used to detect exposure to the virus using a test that can be 
performed on large numbers of pigs at once. Modes of serologic testing include indirect 
fluorescent antibody assays (IFA), immunoperoxidase monolayer assay (IPMA), enzyme-
linked immunosorbent assay (ELISA), and a serum-virus neutralization assay. An IFA is 
subjective and is not automated. An IPMA is also subjective in terms of endpoints, and is 
not automated as well. The ELISA is sensitive and can aid in determination of when the 
infection occurs by comparing immunoglobulin G and immunoglobulin M levels. Last, 
the serum-virus neutralization assay requires fluorescent antibody or immunoperoxidase 
staining to conclude if viral replication is present (Opriessnig et al., 2007).  
Serologic tests are generally used for diagnosis of herds, not individual pigs. Part 
of the reason for this is that pigs may be seropositive and not show any clinical symptoms 
of PCVAD. This should be taken into consideration when serologic tests are performed 
(Gillespie et al., 2009).  
 Grau-Roma and others, in a 2010 review, mentioned that quantitative real-time 
PCR (qPCR) is another method that can be used for determination of infection. Threshold 
levels can be set for blood samples or swabs to test for PCV2; these thresholds will differ 
from lab to lab and therefore consistency can be a problem. Using live animals limits the 
capacity of qPCR, however; there have been issues with specificity and sensitivity, and 
whether qPCR can replace histopathological examinations remains to be seen.  
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Prevention and Control 
 No treatment practices have been developed to combat PCV2 infection thus far. 
Because there is a wide variety of symptoms and range of reactions to infection, it had 
been a challenge to formulate a catchall procedure. Prognosis upon exposure to PCV2 
relies on many factors, including immune status, age at infection, and specific syndrome 
that is manifested.  
 Prevention practices are also variable and inconsistent. Even the farm with the 
strictest vaccination and sanitation protocols can experience an outbreak. Prevention of 
co-infections by vaccinating for other bacteria and viruses can help avert the spread of 
PCV2, but this becomes impractical when so many co-infectious agents exist.  
 Disinfection to thwart PCV2 outbreaks is critical in large farms and research 
settings. In their 2007 review, Opriessnig and others discussed several methods of 
reducing viral replication. These methods, tested in laboratory settings, include: sodium 
hydroxide, Virkon S (Antec International, UK), Roccal D Plus (Parmacia and Upjohn, 
US), Clorox Bleach (Clorox Company, US), and Tex-Trol (Bio-Tek Industries Inc, US). 
Although not tested in commercial settings, these disinfectants have been successful in 
inhibition of the spread of PCV2, when used according to manufacturer’s directions.  
Deterrence of PCV2 infection involves many basic strategies that farms may 
already have in place. Adequate housing management is a vital factor in the prevention of 
PCV2. Reduction of stress on the animals, proper hygiene of employees, and the use of 
an all in/all out strategy can reduce the risk of PCV2 contraction (Gillespie et al., 2009). 
In 2000, Madec and others devised a strategy known as ‘Madec’s 20-point plan’ to 
combat the spread of PCV2. Their plan included procedures such as limited animal 
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contact, proper disinfection, and the isolation or euthanasia of disease pigs in the herd. 
Harding in 2004 also suggested that maintenance of ideal pen stocking density and 
segregation of pigs by age could decrease the spread of PCV2.  
In addition, a list of factors that could decrease the risk of PMWS was discussed 
in Grau-Roma et al. review (2010). These factors include: separate flush pits for separate 
rooms of pigs, shower facilities for employees, sorting pigs by sex at the nursery stage, 
vaccination of sows against atrophic rhinitis, use of oxytocin during farrowing, and use of 
spray-dried plasma in nursery rations. Also outlined was a list of practices that might 
increase the incidence of PMWS, including: high levels of cross-fostering, large range in 
weight and age entering the nursery, and vaccination of gilts against PRRSV.  
 
Vaccinations 
 Several vaccines have been developed to stop the progression of PCV2 associated 
diseases. The first vaccine, Circovac® by Merial, was approved for use in 2007. Since 
then, the FDA has approved four more vaccines for use in the United States.  
 Circovac® is a killed-PCV2 virus vaccine for sows that uses mineral oil as the 
adjuvant. The drug requires 2 mL intramuscular injections about three to four weeks apart 
at least two weeks before mating. A booster vaccine once every gestation period, at least 
two to four weeks before farrowing is scheduled, is also required. The drug is available 
for purchase in both Canada and Europe (Iowa State website). 
 Circumvent™ PCV by Intervet is an inactivated Baculovirus that uses two mL 
intramuscular injections three weeks apart. The vaccine is designed for healthy pigs three 
weeks or older and is sold in the United States and in Canada (Iowa State website). 
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Another vaccine by Intervet, Porcilis® PCV, is a PCV2 capsid that is designed for piglets 
as well, and is delivered with a Diluvac Tocopherol adjuvant. It also requires two 
injections (Burch, 2008).  
 Suvaxyn PCV2® One Dose was developed for healthy pigs four weeks or older. 
The vaccine is available in the United States, and is an inactivated PCV1-2 chimera. The 
vaccine is marketed by Fort Dodge® Animal Health (Iowa State website). It is developed 
with SL-CD aqueous as an adjuvant (Burch, 2008). 
 Last, Ingelvac® CircoFLEX™ is PCV2 expressed in inactivated Baculovirus and 
is delivered in a single dose of one mL intramuscularly. It is designed for piglets three 
weeks of age and older, and is marketed in United States by Boehringer Ingelheim (Iowa 
State website). 
 Numerous studies have been carried out to determine the efficacy of these 
vaccines since their approval in the past years. One such study was performed by Lyoo 
and others (2010) and tested the use of Circumvent™ PCV, Ingelvac® CircoFLEX™, and 
Suvaxyn PCV2®. Four pigs from 20 litters in a natural farm setting were selected and 
assigned one of the above doses, with the fourth pig remaining as a control. All pigs were 
vaccinated using the protocols as established by their respective companies. It was 
determined that the three vaccine groups differed in average daily gain (ADG), in which 
the pigs receiving the Circumvent™ PCV and Ingelvac® CircoFLEX™ vaccines had 
higher ADG than control pigs (P < 0.05). In terms of viremia, only 16.9% of the pigs 
vaccinated with Circumvent™ PCV tested positive for PCV2 DNA; 18.1% of the 
Ingelvac® CircoFLEX™ pigs tested positive; and 15.2% of the Suvaxyn PCV2® pigs 
tested positive. Although they had PCV2 DNA, they demonstrated no clinical symptoms. 
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Another study by Takahagi et al. (2009) tested two vaccines, Porcilis® PCV and 
Ingelvac® CircoFLEX™, according to their manufacturer regulations. A third group was 
not vaccinated and used as controls. A total of 997 pigs were used. It was found that at 24 
weeks, the mortality rate of the Porcilis® PCV-vaccinated pigs was 11%; for Ingelvac® 
CircoFLEX™, the mortality rate was 13%; and for the controls, the mortality rate was 
32%. Mortality rates were drastically reduced after vaccination and therefore use of a 
vaccination against PCV2 is a viable option to reduce the incidence of PCV2 associated 
diseases.  
Although vaccines for PCV2 are relatively new to producers and scientists, they 
seem to be capable of decreasing infection and mortality rates and also increasing ADG. 
Further testing is needed to completely understand the mechanisms and full effects of the 
vaccines.  
 
Genetic Parameters for Selection 
Although there is no infallible method for treatment or prevention of PCV2 
infection, it may be possible to select for animals with an increased resistance to PCV2. 
In a dissertation by Bates in 2008, a selection experiment was carried out to estimate 
genetic and environmental effects of PCVAD. The extensive study involved 3,271 pigs 
from two genetic lines. The lines had been selected over many generations for increased 
reproduction rates and growth. All pigs were transported to one of four locations, which 
included confinement buildings and outdoor lots. The pigs were scored for symptoms of 
PCVAD, including muscle wasting, slowed growth respiratory issues, and diarrhea. 
These scorings were performed approximately every seven to 10 days. Pigs receiving a 
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score of 0 displayed no symptoms and were considered normal. Pigs receiving a one 
score had minor symptoms and were thought of as potential PCVAD pigs. Pigs with a 
two score had obvious signs of PCV2 infection. Pigs receiving a two were sent to 
necropsy, and immunohistochemistry and real-time PCR was performed. All pigs tested 
negative for PRRSV, but co-infection with M. hyopneumoniae was found in 19 pigs. 
Eighteen pigs experienced a co-infection with Streptococcus suis, and four also had 
Lawsonia intracellularis. 
Once the data were analyzed, several significant correlations and heritabilities 
were estimated. The PCVAD scores were compared with weights at birth weight, 
weaning weight, d65 weight, and d180 weight. It was found that birth weight and 
PCVAD score had a moderate positive correlation (r = 0.34, P < 0.10). Also, d65 weight 
had a strong negative correlation with PCVAD score (r = -0.53, P < 0.01). It was found 
that IgG levels at d90 were strongly negatively correlated with PCVAD score  
(r = -0/67, P < 0.001). In terms of direct heritability, PCVAD score had a low direct 
heritability (0.16 +/- 0.04). Birth weight had a moderate heritability (0.27 +/- 0.07). The 
heritability of weaning weight was 0.16 +/- 0.06, and that of both d65 weight and d180 
weight was 0.23 +/- 0.06.  
There were also differences in weights at all time points. At birth, pigs with a 
PCVAD score of 0 differed from those with a score of 1 by 0.10 kg. At weaning, the 
difference was 0.51; at d65, the difference was 3.0; at d180, the difference was 20.9  
(all P < 0.001). This provided significant evidence that infection with PCV2 diminishes 
weight gain, and the problem is exponentially worse the longer the pig is alive.  
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The author suggested that a selection index could be utilized to lower the 
occurrence of PCV2 infection. An index using estimated breeding values (EBV) for traits 
such as PCVAD score and weight could accomplish this. If a pig having low weight at 
d180 and had a positive PCVAD score, this pig could be excluded from the breeding 
herd.  
Bates discussed that selection could help in populations where PCV2 infection 
was consistently high. Although vaccinations appear to help control the spread of the 
virus, they can be costly to producers. Also, every pig must be vaccinated in order to gain 
protection against the virus. Using selection to control disease spread is an alternative that 
would not raise costs significantly to the producer. Selection against PCVAD is reliant on 
exposure to the virus. A pig must receive maternal antibodies, and it turn have them 
wane, to come into contact with the virus. Therefore, selection for PCVAD resistance is 
dependent on exposure to PCV2. 
 
Summary 
Porcine Circovirus 2 is a complex disease with no current treatment regime. 
While the complete pathology of the virus is not understood, steps can be taken to 
prevent outbreaks of the diseases that the virus causes. Vaccines are available but at a 
high cost to producers, so it is becoming increasingly evident that an alternative is 
needed. Genetic selection for disease resistance may become the best option for 
decreasing the prevalence of PCVAD. Because a definite difference in susceptibility of 
certain breeds exists, selection of candidates for reproduction can be used to decrease the 
incidence of PCV2. Because of the high economic impact of viral pathogens in swine 
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herds, genetic resistance is becoming more important as a mechanism to stop the spread 
of infectious diseases such as PCV2.  
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CHAPTER 2: Variation in Response to Both Natural and Experimental Infection 
with Porcine Circovirus 2b 
 
2.1 INTRODUCTION 
 
Porcine circovirus 2 (PCV2) has caused economical problems for producers and 
other members of the swine industry since its discovery in 1996. Infection with PCV2 
can cause a host of other diseases known as PCV2 associated diseases (PCVAD). 
Diseases associated with PCV2 infection elicit a variety of symptoms. The largest losses 
from PCV2 infection have occurred following diagnosis of post-weaning multisystemic 
wasting syndrome, PMWS, which is characterized by an inability to gain weight creating 
a wasting condition, as well as jaundice and lymphocytic depletion (Gagnon et al., 2008). 
Another diseases caused by PCV2 infection include PCV2-associated enteritis, which 
causes diarrhea and inflammation of the colon (Kim et al., 2004). Porcine Respiratory 
Disease Complex elicits retarded growth, lower feed efficiencies, and coughing, and is 
known to be at least partially associated with PCV2 (Kim et al., 2003). PCV2-associated 
reproductive failure, causing abortion and stillborns; and porcine dermatitis and 
nephropathy syndrome (PDNS), which elicits fever, lethargy, and skin lesions (Harding, 
2004). All of these symptoms cause unfit pigs that do not grow enough to reach their 
genetic potential.  
Because there is no treatment for PCV2 infection, it is important to find 
alternative methods to stop the virus. Management practices and preventative measures 
have been introduced and in some cases implicated, but have not been successful in 
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complete eradication of the virus. Vaccines have been proven effective in several studies 
(Lyoo et al., 2010; Takahagi et al., 2009). Although they can efficiently prevent the 
spread of PCV2, vaccines also raise costs for producers and therefore put a strain on the 
industry.  
The studies reported here investigated individual responses to both natural and 
experimental infections with PCV2 in pigs of two crossbred lines. The data were used to 
compare the two genetic lines and understand susceptibility differences between them. 
The objectives were to identify pigs with varying patterns of immune response and to 
determine if there were differences in other measurable traits, including growth, antibody 
level, and viremia. Another goal was to ascertain what components determine why some 
pigs show clinical signs and others do not. These studies represent preliminary efforts to 
establish a large database of tissues, blood samples, and phenotypes from infected 
animals in order to understand the factors that cause variation in immune responses to 
PCV2.  
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2.2 MATERIALS AND METHODS 
 
2.2.1 TRIAL 1 
 
Animals:  All procedures using animals were reviewed and approved by the Institutional 
Animal Care and Use Committee at the University of Nebraska-Lincoln. A composite 
Large White x Landrace cross selected for 29 generations for increased litter size and 
lean growth rate (Line 2, n = 166 representing 41 litters) and a control line with a similar 
genetic background (Line 16, n = 63, 16 litters) were used. Pigs were sired by a total of 
25 boars. Pigs were farrowed at the University Swine Farm located in Mead, Nebraska, 
where routine testing for major pathogens occurs. All pigs were known to be free of 
porcine reproductive and respiratory syndrome virus (PRRSV). Following weaning at 21 
days of age, 229 randomly-selected pigs of both sexes were transferred to a finishing barn 
at the Haskell Agriculture Laboratory in Concord, Nebraska. Pigs were placed randomly 
into 16 pens within one room. Pigs selected for the study were not vaccinated for PCV2; 
however, their dams were. All pigs were allowed ad libitum access to a standard, 
balanced diet supplied by a commercial feed mill. 
 
Serology:  Blood samples were collected on d14, d49, and at necropsy. The blood was 
collected in 7.5 mL BD Vacutainer tubes (Reference #367987, Franklin Lakes, New 
Jersey, USA). After collection, the samples were refrigerated until they could be 
centrifuged at 3500 rpm for 15 minutes at 4°C. The serum was poured off into 1.5 mL 
tubes for storage and the red blood cells remaining in the tube were discarded. Serum 
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samples were tested for the presence of PCV2–IgG and IgM using ELISA (Ingezim, 
Madrid, Spain). Samples were considered positive for IgG if the calculated sample-to-
positive ratio was greater than 0.4. Samples were considered positive for IgM if the 
calculated sample-to-positive ratio was greater than 0.3. 
The initial objective of the trial was to uniformly infect the pigs on the same day 
once maternal antibodies had waned. After infection, the plan was to monitor responses 
in viremia, immunoglobulin levels, and weight gain. However, it was found after the 
second bleeding that the pigs had already been exposed to the virus. The first sign of this 
was some of pigs showing clinical signs of PCV2 infection, including wasting and rough 
hair coats. This was determined by the IgM and IgG levels in the serum, as well as viral 
copy counts, collected at d 49. Because natural infection had occurred, the decision was 
made to not infect the pigs and to perform necropsy on all pigs as soon as possible.  
 
Clinical Evaluation and Necropsy:  Pigs were weighed at move-in (d0), d14, and d49. 
Necropsy was performed on four days because pigs were transported to the UNL Animal 
Science facility where necropsies were performed. Therefore, necropsy was performed 
with 63 pigs on d62, 59 pigs on d63, 54 pigs on d66, and 41 pigs on d69 of the 
experiment. Samples of spleen, lung, and mesenteric and bronchial lymph nodes were 
collected at necropsy. Half of each sample was snap-frozen in liquid nitrogen for future 
gene expression analyses and the other half preserved in formalin for histological 
examination. 
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PCV2 Quantification:  Viral DNA was extracted from blood samples using the QIAamp 
DNA Minikit (Qiagen, Valencia, California, USA). DNA extracts were used for 
quantitative real time PCR quantification (qRT-PCR) and sequencing of PCV2 genomic 
DNA. Two pairs of primers were used for amplification of the PCV2b genome. The PCR 
was performed using GoTaq Flexi DNA Polymerase (Promega, Madison, Wisconsin, 
USA) and standard protocols. Products from the PCR were purified using ExoSAP-IT 
(USB Corporation, Santa Clara, California, USA) and sequenced from both directions 
using dye terminators on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, 
Carlsbad, California, USA). A list of primers and probes used for both qRT-PCR and 
sequencing of the PCV2 genomic DNA is included in Table 1. BioEdit software (Ibis 
Therapeutics, Carlsbad, California, USA) was used to assemble and analyze the 
sequences.  
 
Genotyping:  A total of 110 pigs were genotyped using the PorcineSNP60 BeadChip by 
Illumina Inc. (San Diego, California, USA). These pigs were selected using SAS PROC 
PRINCOMP, principal component analysis, a multivariate method to look at relationships 
among many variables. The principal component analysis indexes animals based on the 
score given by the analysis, and the top 55 and bottom 55 were selected for genotyping. 
The PorcineSNP60 chip has both allelic-specific primer extension and single-base 
extension. The assay is based on direct hybridization of the whole genome-amplified 
DNA to a bead array of 50-mer specific probes. Once attached to the probe, the beads are 
pooled, arrayed randomly, and assembled into the wells of the slide. The hybridization of 
probe to DNA is followed by an enzymatic-based extension assay using DNA 
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polymerase and labeled nucleotides. The labels are stained and each single nucleotide 
polymorphism (SNP) is then scored.  
 
Sequence Analysis and Alignment:  The viral DNA was isolated from ten individuals 
showing signs of disease and sequenced. Sequencing was performed from both directions 
using dye terminators on an ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). 
This sequence, which matched in each individual, was aligned and entered into BLAST 
(Basic Local Alignment Search Tool) to find the PCV2b strain with the highest sequence 
identity.    
 
Statistical Analysis:  Correlations among variables (IgG, IgM, weight changes, and 
viremia) were estimated using PROC CORR of SAS software (SAS Institute Inc., Cary, 
North Carolina, USA). No fixed effects were included in the model.  
 The genotypes of each SNP were analyzed using GenCall Data Analysis Software 
(Illumina, San Diego, California, USA). Each SNP genotype was given a GenCall Score 
to sort out failed genotypes, DNA, or loci. This GenCall Score is based on the reliability 
of the SNP assay, DNA, or ability of a genotype call to cluster in genotype groups. The 
data was analyzed using JMP software (SAS, Cary, North Carolina, USA) and sorted by 
SNP position. This information was used to make overlay plots for both minor allelic 
frequency and Hardy-Weinberg Chi Square tests for both Trial 1 and Trial 2. 
 Gene associations were made using ASREML software (VCN International, 
Hemel Hempstead, United Kingdom). The software is a statistical package to fit linear 
mixed models using restricted maximum likelihood to fit large data sets. Each SNP from 
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BeadArray was assessed for association with PCVAD phenotypes using the ASREML 
package, with pen as a random effect, genotype as a fixed effect, and based on an 
extensive pedigree over six generations. Additive and dominance effects as well as an F 
value for each SNP were estimated. A false discovery rate was estimated for additive and 
dominance effects for every marker. Following analysis in ASREML, the data was 
entered into JMP for the creation of Manhattan plots to illustrate the genome-wide 
association studies.  
  
 
2.2.2 TRIAL 2 
 
Animals:  All procedures using animals were reviewed and approved by the Institutional 
Animal Care and Use Committee at the University of Nebraska-Lincoln. The experiment 
included 91 crossbred barrows from 24 litters. Pigs were either a two-way cross of Large 
White and Landrace (W x R, n = 72) or three-way crosses produced by mating Duroc 
sires with Large White x Landrace sows [D (W x R), n = 19]. Pigs were farrowed at the 
University of Nebraska Swine Farm in Mead, Nebraska, where routine testing for major 
pathogens occurs. All pigs were known to be free of porcine reproductive and respiratory 
syndrome virus (PRRSV). Pigs selected for the study were not vaccinated for PCV2, 
although their dams were.  
At approximately 35 days of age, the pigs were moved to the Animal Science 
research facility for the infection experiment. The barrows were housed in one room of 
the building and randomly assigned into one of 18 identical pens. The pens contained a 
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combination of slatted and solid surface flooring. The pens allowed each pig 
approximately 0.65 m2 of floor space, which exceeds standard space requirements for 
pigs of that age. All pigs were allowed ad libitum access to a standard, balanced diet 
manufactured at the ARDC feed mill. 
 
Experimental Infection:  The objective was to infect pigs with PCV2b virus after 
protection from maternal antibodies had waned. Another factor in the timing of the 
infection was to infect as soon as possible because of the threat of a natural infection. 
Blood was drawn from pigs at the University Swine Farm in Mead, Nebraska, before the 
pigs were transported to the Animal Science facility. The blood was analyzed for 
immunoglobulin G (IgG), which is an indicator of maternal antibodies, using an ELISA 
(Ingezim, Madrid, Spain). The sample-to-positive ratio of IgG in all individuals selected 
for the experimental infection was less than 0.3 at the time of inoculation. This level is 
specified by Ingezim as negative for antibodies. In addition, immunoglobulin M (IgM) 
was tested as an indicator of self-antibodies produced in response to infection. Sample-to-
positive ratio was less than 0.4, the cut-off recommended by Ingezim, showing that 
natural infection had not occurred.  
The virus inoculum contained the titer of 104.0 50% tissue culture infection dose 
(TCID50)/mL in minimum essential media with 50 ug/mL gentamicin and 5% fetal calf 
serum. The original experimental protocol was to infect each pig with 2 mL of inoculum 
intramuscularly (IM) and 3 mL intranasally (IN). However, approximately 20 minutes 
after inoculation of 20 pigs, anaphylactic shock occurred in 10 pigs and eight of them 
died. Twelve pigs inoculated with 2 mL IM and 3 mL IN survived. The dose 
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administered to the remaining pigs was therefore altered. Most of the pigs (n = 58) 
received 1 mL IM and 3 mL IN. The rest of the pigs received a variation of this dose: 1 
mL IM with 0.5 mL IN (n = 4) or 2 mL IM with 0.5 mL IN (n = 8). The pigs used for 
these treatments were chosen at random. Ten pigs were selected as negative controls, 
assigned to separate pens, and not inoculated.    
PCV2b Isolate:  Isolate UNL_VBMS was taken from a pig showing symptoms of 
PCV2b infection. Viral DNA was isolated using QIAamp DNA Minikit (Qiagen, 
Valencia, California, USA). Two pairs of primers were used to amplify the entire PCV2b 
genome. Amplification of DNA was performed using GoTaq Flexi DNA Polymerase 
(Promega, Madison, Wisconsin, USA), and PCR products were purified using ExoSAP-
IT (USB Corporation, Santa Clara, California, USA). Viral DNA was sequenced from 
both directions using dye terminators and ABI PRISM 3100 Genetic Analyzer (Applied 
Biosystems, Carlsbad, California, USA). Sequence analysis using BLAST revealed that 
the strain used for inoculation was most similar to strain FMV-05-6507. This strain was 
identified first in Quebec, Canada in 2005 and is known to induce clinical signs of 
PMWS and cause an increase in mortality rate.   
Serology:  Blood samples were collected before inoculation and at 7, 14, 21, and 28 d.p.i. 
(days post infection). The blood was collected into sterile 7.5 mL tubes (BD Reference 
#6530) and then separated into two tubes: half the blood went into the BD Vacutainer 
tubes used in trial 1, and the other half went in 7.5 mL Tempus Blood RNA tubes. These 
tubes contain an RNA stabilization solution that must be shaken vigorously once in 
 57 
contact with blood, and are manufactured by Applied Biosystems (Carlsbad, California, 
USA). The blood in the BD tubes was refrigerated until it could be centrifuged at 3500 
rpm for 15 minutes at 4°C to obtain serum. The Tempus tubes were frozen at -20°C for 
storage. Levels of PCV2-specific antibodies, IgG and IgM, were measured from serum 
using ELISA. Samples were considered positive if the calculated sample-to-positive ratio 
was greater than 0.3 for IgG and 0.4 for IgM. Antibody data were normalized based on 
positive control values obtained on each plate.   
Clinical Evaluation and Necropsy:  Pigs were observed daily for clinical signs of 
infection, and were weighed at 0, 7, 14, 21, and 28 d.p.i. Necropsy was performed at 28 
d.p.i. Lung, spleen, and mesenteric and bronchial lymph nodes were collected for 
histological examinations and gene expression analysis.   
PCV2 Quantification:  Viral DNA was extracted from serum collected at 7, 14, 21, and 
28 d.p.i. using QIAamp DNA Minikit. Estimates of viral copy number were obtained by 
quantitative real-time PCR using TaqMan Master Mix and ABI7900 (Applied 
Biosystems, Carlsbad, California, USA). A list of primers and probes used for both qRT-
PCR and sequencing of the PCV2 genomic DNA is included in Table 1. The area under 
the curve (AUC) was calculated to estimate total viral load throughout the 28-day 
experimental infection.  
Genotyping:  All infected pigs were genotyped using the PorcineSNP60 BeadChip by 
Illumia Inc. (San Diego, California, USA). This chip is described in Section 2.2.1.  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Sequence Analysis and Alignment:  The PCV2 strain used in experimental infection was 
isolated from a pig with PCVAD symptoms, cultured and sequenced. Viral DNA from 
four pigs of each IgM group (early, late, and no responders) was sent for sequencing to 
confirm that they were infected with the same strain. Sequences were aligned using 
Sequencher software (Gene Codes Corporation, Ann Arbor, Michigan, USA). Once 
aligned, the sequences were entered into BLAST (Basic Local Alignment Search Tool) to 
find the sequence with the highest sequence identity.  
Statistical Analysis:  Least Squares Means (LSM) were obtained using mixed-model 
procedures including the immune response pattern with crossbred lines as fixed effects 
and pen and litter as random effects. The variables included in the model were IgG, IgM, 
viremia, and ADG at all time points. Analysis of the IgM antibody profiles during the 
challenge revealed that infected individuals could be characterized by three patterns of 
immune response and could be separated in three groups. Most pigs clearly fitted into one 
of these groups, but in some cases pigs were placed in a group based on a subjective 
judgment.  Correlations among traits were calculated from variances and covariances 
adjusted for line effects.  
 The genotypes of each SNP were analyzed using GenCall Data Analysis Software 
as described in Section 2.2.1. This information was used to make overlay plots for both 
minor allelic frequency and Hardy-Weinberg Chi-Square tests using the data from both 
trials. 
 Gene associations were made using ASREML software (VCN International, 
Hemel Hempstead, United Kingdom) as described in Section 2.2.1. The model included 
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pen, litter, and genetic line as random effects, and genotype as a fixed effect. Following 
analysis in ASREML, the data were entered into JMP for the creation of Manhattan plots 
to illustrate the genome-wide association studies.  
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2.3 RESULTS AND DISCUSSION 
 
2.3.1 TRIAL 1 
 
Serology:  All pigs used for the challenge came from dams that were vaccinated against 
PCV2. The pigs received maternal antibodies, specifically IgG, through colostrum from 
the dam during nursing following birth. Results from ELISA indicated that on d14, which 
was the first bleeding time point, 23 of 217 pigs (10.6%) were positive for IgG. Because 
the pigs were not bled before moving into the facility to check for maternal antibodies, it 
was deduced that the differences among pigs was due to the rate of maternal antibody 
decay varying from one individual to the next. However, IgG levels were much higher at 
d49 with 148 of 217 pigs (68.2%) being positive, indicating that infection had occurred 
between these time points and the immune system was mounting a secondary response to 
the virus. At necropsy, 198 of 217 pigs (91.2%) had a high enough sample-to-positive 
ratio to be considered positive for IgG.  
 In terms of IgM, a very low percentage of pigs were positive at d14, only two of 
217 (0.009%.) Because IgM is a measure of individual primary response to an immune 
stressor, it was determined that these pigs were experiencing PCV2 infection. The two 
infected pigs were housed in pens two and six. Because so many pigs were serologically 
positive for IgM at the next bleeding on d49 (77.4%), it seemed that these two pigs could 
have spread the virus throughout their pens and consequently to other pens. This is 
possible because the pens that housed the pigs had metal bars with approximately six 
inches of distance in between. This was enough room for the pigs to touch snouts 
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between the bars. Because nose-to-nose contact is a common mode of transmission, it is 
logical to assume that the virus started in two pens and was spread throughout the barn in 
a 35-day period. The number of positive pigs was somewhat lower at necropsy (72.4%). 
The modest decrease could be due to the fact that some of the pigs had already mounted 
an immune response against the virus. Once anti-PCV2 IgM had peaked after infection, it 
tended to decline.  
This decline in IgM values has been demonstrated in previous studies done by 
Opriessnig et al. (2006). PCV2-specific IgM antibodies in the pigs infected with the 
strain PCV2-4838 peaked at d21 and began to decline by d28 post-infection. The levels 
of IgM in the pigs infected with the strain PCV2-40895 in their study were even higher, 
but followed the same declining trend. At necropsy, IgM response had started to drop for 
some of the pigs, but remained high for others. Also, new infections could have occurred 
between d49 and necropsy, so pigs that had had lower IgM values could have started to 
see an increase. 
 
PCV2 DNA in Serum:  Real-time quantitative PCR establishment of viral copy counts 
indicated that at d14 all pigs were negative for PCV2 viremia. At d49, the second 
bleeding, least squares means of all pigs was 3.75 viral DNA copies per mL serum  
(log 10) (P < 0.0001 for test of mean greater than 0). At the last bleeding at necropsy, 
least squares means for all pigs was 3.58 viral DNA copies per mL serum (log 10)  
(P < 0.0001). There were no differences between lines for viremia at any time point 
(Figure 1). For area under the curve for viremia, the least squares mean was 127.9 viral 
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DNA copies per mL serum (log 10) (P < 0.0001). This statistic helps to explain the entire 
viral load that each animal experienced throughout the trial. 
 These results indicated that there was a steady increase in viremia throughout the 
infection period. This also showed that the pigs were unable to mount an adequate 
defense against the virus. As more pigs came into contact with the virus, it became 
increasingly harder to avoid becoming ill. It seemed that the viral copy counts peaked 
somewhere between d49 and necropsy. This sheds a little light on the timing in which the 
pigs first contracted the virus. This information can be combined with the fact that IgM 
levels spiked from d14, when only two pigs were positive, to d49, when 168 pigs were 
positive. Likely, around d49 the highest number of pigs were infected, and the highest 
viral copy counts were present in their DNA. Unfortunately, without more frequent 
testing, it is impossible to know the exact point of infection for each individual.  
 
Clinical Evaluation:  At necropsy, the following clinical signs were observed: evidence 
of mycoplasma (n = 14), enlarged mesenteric lymph nodes (n = 10), interstitial 
pneumonia (n = 3), enlarged bronchial lymph nodes (n = 2), edema (n = 2), abscesses of 
the spleen and liver (n = 2), peritonitis (n = 1), and polyserositis (n = 1). In addition, 12 
pigs died before the conclusion of the trial, either in the pens or during the transportation 
process to the kill facility. Necropsy could not be performed on these animals.  
 
Genetic Characterization of the PCV2b Isolate:  Virus was isolated from ten individuals 
showing signs of disease and sequenced. It was established that the source of infection 
was a PCV2b strain, and was named UNL_ANSCI. It was found to have three 
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nucleotides that differed from the strain being developed for inoculation of the second 
round of pigs, Trial 2.  
 
Genotyping:  The PorcineSNP60 BeadChip was used to genotype 110 animals from Trial 
1, and provides sufficient density in order to identify either markers or groups of markers 
that are in association with deviations of physiological traits. There were 62,163 SNPs, 
and the low GenCall Score Cutoff was 0.15. The GenCall Score Cutoff is calculated for 
each genotype and ranges from zero to one. Because the scores decline when the sample 
is further from the center of the cluster when the data point is associated, genotypes with 
a Gencall score of less than 0.15 are considered not “quality” and are not given a 
genotype. The average call rate of the 110 animals was 99.53%, and the average number 
of calls per animal was 59,613. The average number of no calls, in which the genotype 
could not be called with accuracy, was 281. The average heterozygosity was 24.9% for 
the 110 pigs genotyped. 
 Figure 2 illustrates overlay plots of minor allelic frequency versus SNP position at 
each chromosome for all pigs genotyped in both trials. For example, on SSC 11, between 
32 and 41 Mb, the minor allelic frequency of a large number of SNPs is below 0.2. A 
similar approach was used to identify a chromosomal region where clusters of SNPs are 
in Hardy Weinberg genetic equilibrium (Figure 3). An example of this is on SSC1, at 
approximately 14 Mb, where there is a cluster of SNPs. Another cluster on SSC1 is 
between 27 and 28 Mb. SSC9 shows a cluster occurring between 60 and 61 Mb. These 
plots can be used to discover errors in genotyping methods as well. On SSC1, a SNP at 
 64 
17 Mb appears to be informative because of its spread, but is likely due to genotyping 
error since it is one data point and not a cluster.   
Both approaches can be used to uncover regions of the genome where selection is 
affecting the frequency of beneficial alleles by driving them either up or down. Genetic 
dissection of this region could uncover functional polymorphisms for traits of economic 
importance.  
 
Gene Associations:  The software package ASREML was used to determine genome-
wide associations between the SNP genotypes for the 110 pigs genotyped and PCV2-
specific traits- IgM, IgG, viremia, and ADG. 
 
Correlations: There was a moderate positive correlation between the changes in weight 
from d1 to d14 with IgG at d49 (0.24, P < 0.05). Another positive correlation existed 
between change in weight from d1 to d14 and IgG at necropsy (0.16, P < 0.05). 
Correlations are given in Table 2. Because these correlations were weak, they cannot be 
used to draw exact conclusions about the variations in immune reaction that occurred 
during the trial. 
 
Implications:  The pigs in this natural infection experienced a variable response to 
infection with PCV2. Evidence of infection was found in 77.4% of pigs at d49 in terms of 
IgM response. Also the least square mean of viremia at this time point was 3.75 viral 
DNA copies per mL serum (log 10) at this time point. However, only 16.1% of the pigs 
had developed clinical symptoms of PCVAD. This is indicative that the patterns of 
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immune response differed among the pigs. Some of the pigs that were infected showed 
no clinical signs, and continued to grow at a normal rate throughout the experiment. 
These pigs were ideal because they could overcome the effects of the virus and still 
eventually reach a suitable market weight. Only a few of the pigs were very negatively 
affected by the virus and suffered from respiratory complications and stunted growth. It is 
important to be able to select against the pigs that showed clinical signs in order to have 
pigs remain healthy and grow to their potential. 
Although it was difficult to draw definitive conclusions because of a variance in 
both timing of infection and amount of virus each pig was exposed to, it is important to 
understand that the immune response mounted for each pig differed. This preliminary 
study adequately set up the next trial to understand individual responses to infection with 
PCV2 in two different lines.  
  
 
2.3.2 TRIAL 2 
 
Serology:  All pigs used for the challenge came from dams that were vaccinated against 
PCV2. The pigs received maternal antibodies, specifically IgG, through colostrum from 
the dam at birth. Antibody decay varies in piglets but on average will wane by 5 to 21 
weeks. Of the initial 120 candidates for infection, 75% had antibody levels low enough to 
begin the infection process. This was determined by ELISA and a sample-to-positive 
ratio of less than 0.3 for IgG. Overall, 82% of the Large White x Landrace (W x R) pigs 
had IgG levels below the threshold (n = 82). Comparatively, 58% of the Duroc x Large 
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White x Landrace [D (W x R)] had levels low enough to infect (n = 31). The levels of 
IgG in the two crossbred groups did not differ (P > 0.1) before infection. Throughout the 
trial, there was no difference in IgM (Figure 4) or IgG (Figure 5) levels between the two 
genetic lines, W x R and [D (W x R)]. 
After infection, pigs were classified into one of three groups according to IgM 
response. This is demonstrated in Figure 6. Those pigs that had the highest change in IgM 
levels before d14 were classified as early responders (n = 33), and were placed in Group 
1. Individuals that had the highest change in IgM levels after d14 fit into Group 2  
(n = 40) and were called late responders. Group 3 consisted of pigs that did not respond 
to infection (n = 7); that is, they did not have a noticeable change in IgM levels.  
  IgM levels during the experiment indicated that an infection had occurred and that 
the barrows were building a primary response. At d7, there was no difference in IgM 
levels between the three groups and the controls. At d14, Group 1 had the highest IgM 
level with a mean of 1.38, whereas the mean for Groups 2 and 3 were 1.04 and 0.89, 
respectively. At d21, Group 2 had the highest IgM levels at 2.02, whereas Group 3 
remained the lowest and Group 1 was intermediate. At necropsy (d28), Group 2 remained 
highest and Group 3 lowest. This indicates that in Group 3, with baseline IgM levels of 
about 0.89 throughout the challenge, no quantifiable change in IgM levels occurred, and 
therefore those pigs did not undergo a primary immune response (Figure 7). 
 There was no differences among the three groups in IgG levels, at d0 and 7. At 
d14, Group 1 and Group 2 differed in IgG levels (P < 0.05). At d21, Group 1 differed 
from Group 3 (P < 0.05), and there was a difference between Group 2 and 3 (P < 0.05) as 
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well. At necropsy, Group 1 differed from Group 3 (P < 0.001) and Group 2 differed from 
Group 3 (P < 0.0001) (Table 3). 
Differences in both the magnitude and time of IgM response were observed 
during the experimental challenge with PCV2b. The three groups of IgM response 
experienced variance in response patterns (Figure 6). The chief difference between Group 
1 and Group 2 was in the time of response. This was demonstrated by the peaks of IgM 
before d14 in Group 1 and between d14 and d21 for Group 2. Because all of the pigs 
were infected at the same time, and because there was no difference in IgG levels at d0 
when infection occurred, it is unlikely that they had sufficient maternal antibodies to 
attack the virus.   
Group 3 differed from the other two groups in the magnitude of response. Levels 
of IgG were higher in Group 1 than Group 3 at d21 and necropsy (P < 0.05 and  
P < 0.001, respectively). Also, Group 2 had higher levels of IgG at d21 (P < 0.05) and 
necropsy (P < 0.0001) (Table 3). Therefore, Group 3 was utilizing some other mechanism 
to prevent infection from spreading throughout the body. There seemed to be an 
inhibition of viral replication that allowed these pigs to remain healthy and avoid 
subclinical signs of the virus.  
 
PCV2 DNA in Serum:  Quantitative PCR results for viral copy count indicated that all 
barrows were PCV2 DNA negative at the day of infection. At all other time points, all of 
the pigs that received the inoculation tested positive for infection with PCV2. Differences 
in viral copy numbers between the two crossbred lines existed at d7 (P < 0.006) and d14 
(P < 0.01) as illustrated in Figure 8. However, DNA copy number followed the same 
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trend throughout the challenge for both lines: there was a steady increase in copy number 
through d21, then a sharp decline thereafter.  
 Pigs in Group 3, those who had no noticeable change in IgM values, maintained 
lower viral copy numbers than pigs in both Groups 1 and 2. At d7, Group 1 had the 
highest response at 4.56 viral DNA copies per mL serum (log 10), whereas the response 
in Group 3 was 3.85. At d14, Group 2 had the highest response with a mean of 5.24, 
whereas the mean for Group 3 was only 4.27. At d21, the mean for Group 2 continued to 
be highest, and Group 3 was lowest. At d28, the day necropsy was performed, Group 2 
remained highest in viral copy count, while Group 3 remained lowest. Viremia area under 
the curve (AUC), a measure of overall viral load throughout the challenge, revealed 
Group 3 had the lowest AUC and thus the least viral load and Group 2 the highest. 
Viremia in the control pigs remained baseline during the challenge and had no peaks or 
spikes (Table 3).  
 The dose of inoculate administered to the pigs did not influence viral copy count, 
with the exception of viremia results on d7 (P < 0.05). However, only four pigs showed 
significant differences from the others, and they received the lowest dose of all groups of 
infected pigs. 
 
Clinical Evaluation:  Only one death occurred during the 28-day experimental challenge. 
This individual died during the fourth week of the challenge and displayed signs of a 
wasting condition, as well as lethargy and a rough hair coat. According to quantitative 
real-time PCR, this individual had the highest viral load three weeks after the challenge, 
and was categorized in Group 1, the early response group.  
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 The only difference in growth occurred between Group 1 and 2 in terms of 
average daily gain (ADG) during the entire 28-day period. Group 1 had an ADG for the 
whole challenge of 0.42 kg, whereas pigs in Group 2 had an ADG of 0.36 kg for the 
challenge (P < 0.05). Pigs in Group 3, those with no detectable immune response, had the 
greatest ADG and a trend toward having the best growth rate (P = 0.19).   
 
Genetic Characterization of the PCV2b Isolate:  The strain isolated, sequenced, and 
aligned from 12 infected individuals belongs to a PCV2b cluster and has the highest 
similarity with strain FMV-05-6507. This strain has been shown to induce clinical signs 
of PMWS and cause an increase in mortality rate. Upon alignment of the sequence used 
for infection and the 12 sequences recovered from infected pigs, it was determined that 
the strain used for infection was identical to the strain found in the 12 pigs whose DNA 
was sequenced.   
Genotyping:  All 81 individuals from Trial 2 were genotyped using the PorcineSNP60 
chip. The number of SNPs was 62,163 and the Low GenCall Score Cutoff was 0.15. The 
average call rate was 99.65%, and the average number of calls for the 81 pigs was 
59,687. The average heterozygosity of the 81 pigs was 33.8%. Figure 2 illustrates overlay 
plots of minor allelic frequency versus SNP position at each chromosome for all pigs 
genotyped in both trials. A similar approach was used to identify a chromosomal region 
where clusters of SNPs are in Hardy Weinberg genetic equilibrium (Figure 3). These 
figures are explained in the Section 2.3.1.  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Gene Associations: The software package ASREML was used to determine genome-
wide associations between the SNP genotypes and PCV2-specific traits- IgM, IgG, 
viremia, and ADG. The association between SNP genotypes and IgM at d21 is illustrated 
in Figure 9.  
On chromosome 1, two SNPs were discovered. The first gene connected with a 
SNP was syntaxin 11, also known as STX11. This gene encodes a member of the protein 
group of syntaxins that works in intracellular movement. Syntaxin 11 is primarily 
expressed in phagocytes and antigen presenting cells. Its role in vesicle trafficking may 
play a role in the granule secretory pathway. This gene is known to cause familial 
hemophagocytic lymphohistiocytosis in humans (Danielian et al., 2009). 
Another SNP found on chromosome 1 was GNAQ, also known as guanine 
nucleotide binding protein. This protein encodes the alpha subunit of heterotrimeric G 
proteins. The role of these proteins is to attach the seven-transmembrane domain 
receptors to allow for intracellular signaling (Van Raamsdonk et al., 2010). Mutations in 
the protein cause a mutation known as dominant dark skin that is characterized by 
increased dermal melanin (Emley et al., 2011). 
A SNP on chromosome 6 associated with IgM was close to the interleukin 34 (IL-
34) gene. Interleukin 34 is found in many tissues of the human, including lung, liver, 
kidney, and in abundance in the spleen. This member of the cytokine family plays a role 
in regulation of myeloid cell growth and differentiation. It has also been shown to 
encourage the formation of a macrophage progenitor in human bone marrow cultures 
(Lin et. al, 2008). 
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In addition, there were two possible SNPS associated with IgM on chromosome 
14. The first, positioned near the G protein-coupled receptor kinase 5 gene (GRK5), is in 
family of serine/threonine kinases that assist phosphorylation of seven-transmembrane-
spanning G protein-coupled receptors. The variety of receptors that they have effects on 
include adrenergic, muscarinic, and chemokine receptors. The fifth kinase in the family 
specifically phosphorylates a transcriptional factor and tumor suppressant, p53, which is 
a regulator of both apoptosis and proliferation. In mice, deletion of GRK5 results in 
hypothermia, hypoactivity, tremors, and increased salivation (Chen et al., 2010). 
Last, also on chromosome 14 was a SNP located near the TIAL1 locus (TIA1 
cytotoxic granule-associated RNA binding protein-like 1). This protein is involved in 
nuclear and cytoplasmic RNA metabolism, and is important in splicing regulation in 
mammals. It also has been found to be a translational regulator to assist cellular and 
virus-induced apoptosis, specifically by adapting the cellular response to deal with 
metabolic stress and inflammation (Bossowski et al., 2010). 
  
Correlations:  Moderate negative correlations existed between average daily gain (ADG) 
and viremia area under the curve (AUC) for several time points. These values are located 
in Table 4. Viremia AUC from d0 to d7 was correlated with ADG for the whole 
challenge (-0.22, P < 0.05). Viremia AUC from d0 to d14 had a correlation of -0.24 with 
ADG for the whole challenge (P < 0.05). The correlation between AUC from d0 to d21 
and ADG from d0 to d28 was -0.27 (P < 0.05). The strongest correlation was between 
AUC for the whole trial and ADG for the whole trial at -0.29 (P < 0.01). This correlation 
indicated that the higher the viral load of the pig, the less it would be able to put on 
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weight and grow to its genetic potential. Figure 10 illustrates the correlation between the 
Z score values for AUC PCV2 copy number and ADG, with each dot representing a pig. 
Pigs in the lower right corner demonstrated the most desirable phenotype, with the 
highest grow rates and the lowest viremia.  
 These correlations help to understand the effects of disease progression of PCV2 
on pigs in the grow-finish stage. Pigs with high viremic conditions struggle to catch up 
with their littermates and siblings because with viral replication comes certain wasting 
conditions. Though it has not been demonstrated that feed intake suffers during a period 
of experimental infection such as this, it has been shown in numerous studies that growth 
has been stunted in pigs infected with PCV2.  
 A study done by Blanchard et al. (2003) compared vaccinated pigs to 
unvaccinated pigs in terms of PMWS disease progression. They challenged 28 pigs of 
various immune statuses, with one group being unvaccinated. Ten to 14 days after 
infection, all of the challenge-control group (pigs that were not vaccinated and were 
challenged with the virus) developed both pyrexia and growth retardation. On the other 
hand, pigs inoculated against the virus had significantly higher growth at both the second 
and third week post infection. 
 Albina et al. (2001) found similar results when they studied the effects of direct 
transmission on piglets. Two of the piglets with signs of PMWS before the experiment 
showed signs of emaciation, weakness, and had a high rate of weight loss. These two 
piglets had to be euthanized before the trial ended. The rest of the piglets underwent one 
of their nine trials and were either inoculated with PCV2 or kept as controls. It was 
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shown that all infected pigs developed both pyrexia and growth retardation after about 13 
days of infectious status.  
 
Implications:  Differences in the magnitude and time of IgM response was observed 
during experimental challenge with PCV2b. The difference between Group 1 and Group 
2 was in the time of response, while the difference between Groups 1 and 2 and Group 3 
was in the magnitude of response. Group 3 had the lowest viral copy count and the 
highest growth, most likely due to a mechanism that inhibited viral replication. The pigs 
in Group 3 demonstrated the most desirable phenotype, one in which the pigs’ immune 
system never mounted a response to the disease while also having the propensity toward 
having the best growth rates. Following studies will be aimed at understanding and 
characterizing the mechanism in which these pigs deal with a viral infection such as 
PCV2. Once research has been completed to explain the response to viruses, selection 
against those pigs susceptible for PCVAD will lead to healthier, faster growing pigs. 
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2.4 CONCLUSION 
 
 The results of this preliminary research provide evidence of a significant variation 
in immune response from one individual to another. The natural infection illustrated that 
some infected pigs showed clinical signs to the disease while other infected pigs did not 
elicit symptoms. It also helped explain transmission patterns and virus progression. The 
experimental challenge revealed three groups of pigs that differed greatly in both 
antibody response and viral copy count numbers. It also demonstrated that some pigs 
utilized a mechanism of inhibition of viral replication that is not clearly understood.  
 With a virus like PCV2, several challenges exist. First, the virus is present 
everywhere in the world, and is very hard to disinfect against. Almost every herd in the 
United States has been exposed to the virus. This makes the development of pigs that are 
specific pathogen free for PCV2 extremely difficult. Sows must to be vaccinated against 
the virus to protect against stillborns, abortions, and fetal mummies. This creates 
logistical problems because piglets must be virtually free of maternal antibodies to 
accurately simulate a disease challenge. Therefore, a waiting period must be undergone 
that differs for every pig. Knowing and synchronizing when each pig is ready for 
infection is a practical factor to consider. In the case of a natural infection, it becomes 
difficult to understand infection dynamics when there is such a variation in infection. 
When the exact timing of the occurrence of infection cannot be determined, the variation 
in response times and magnitudes is due to numerous uncontrollable factors. In addition 
to the standard environmental and litter effects, pigs infected at different times with 
different amounts of virus cannot be uniformly studied. 
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 Another challenge is that pigs must be closely monitored to catch clinical 
symptoms and subclinical infections. This means frequent bleedings to test for anti-PCV2 
antibodies and viremic conditions. Regular bleedings, more frequent than once a week, 
can put a strain on the pigs, as well as require an immense amount of labor and time. 
Sensitive tests such as ELISA work well for diagnosis, but make the question of exact 
timing of infection difficult unless the pig is bled daily, a practice that can put the animal 
in danger.  
In Trial 2, the experimental infection, there were clear differences in the groups of 
pigs that had an early or late response versus the group showing no response. A lack of 
immune response has several explanations. One such elucidation is that the pigs were 
infected with different strains of the virus. Since pigs are so susceptible to pathogens in 
new environments, this argument is relevant. However, upon isolation and sequencing of 
the virus from four pigs in each IgM group (1, 2, and 3), the virus infecting the animals 
was found to be identical. This indicates that the lack of response to infection of the 
Group 3 pigs cannot be attributed to a difference in virulence. 
 Another possible suggestion is that the pigs had variable levels of maternal 
antibodies (IgG) circulating in their system from colostrum at the time of birth. However, 
the IgG ELISA confirmed that pigs in each group had no significant differences in IgG 
levels at d0 before infection (P > 0.05). All three groups of pigs, as well as the controls, 
were negative for maternal antibodies, thus the reason they were selected for the 
experiment. A difference in maternal antibodies cannot explain the variation in IgM 
response of the three groups.   
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 A genetic effect could certainly exist. Because the groups of pigs constituted two 
genetic lines, the incidence of viral infection could be due to a susceptibility factor. 
However, analysis of the two lines indicated that there was no significant difference in 
viremia, IgG, IgM, or weight gain between the Large White x Landrace pigs and the 
Duroc x (Large White x Landrace) pigs. Although a genetic component to disease 
resistance has been demonstrated in several studies, the variation in response in this study 
cannot be solely attributed to genetics.  
 There is significant evidence that selection for disease resistance is not only 
possible but also may answer many questions. However, without a panel of reliable 
markers, selection criteria are lacking. Genome-wide association studies to better 
understand the genes responsible for resistance to diseases may be key to understating a 
complex disease like PCV2. More research is needed to establish an extensive database 
of not only phenotypes but also genotypes, SNPs, and candidate genes to better 
understand progression and prevention of the virus. In order to achieve this, many more 
experimental infections must be conducted to better understand the mechanisms, timing, 
and variance in response to PCV2 infection. 
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TABLES 
 
Table 1. Primers and probe sequences used for qRT-PCV and cDNA sequencing of 
PCV2b - Trial 1 and 2. 
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Table 2. Correlations between IgM, IgG, and change in weight at all timepoints - Trial 1.  
 
 Change in Wt, d1 to d14 Change in Wt, d14 to d49 Wt Change Total 
IgM d14 -0.02 0.10 0.07 
IgG d14 -0.08 0.13 0.07 
IgM d49 0.12 -0.01 0.03 
IgG d49 0.24a 0.05 0.12 
IgM Necropsy -0.03 -0.08 -0.07 
IgG Necropsy 0.16a 0.06 0.10 
 
aIndicates P < 0.05 
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Table 3. Least Squares Means of the parameters profiled during challenge in the groups 
of individuals that showed different patterns in immune response to infection - Trial 21. 
 
 
Group  
Trait 1 
n = 33 
2 
n = 40 
3 
n = 7 
Control 
n = 9 
ADG, 0 to 7 d.p.i.2 0.21 0.15 0.18 0.21 
ADG, 7 to 14 0.36 0.32 0.37 0.37 
ADG, 14 to 21 0.49 0.43 0.47 0.55 
ADG, 21 to 28 0.59 0.53 0.63 0.53 
ADG, 0 to 28 0.42a 0.36b 0.43 0.42 
IgG 0 0.76 0.79 0.68 0.83 
IgG 7 0.75e 0.78c 0.75c 0.94f,d 
IgG 14 0.68a 0.61b 0.61 0.69 
IgG 21 1.71c,a 1.83e,a 0.91b 0.70f,d 
IgG 28 1.89g,e 2.08g,i 0.74f,j 0.56h 
Viremia 7 4.56e 4.37c 3.85 3.22f,d 
Viremia 14 5.16g,a 5.24g,a 4.27g,b 2.13h 
Viremia 21 5.8g,c 6.17g,e 4.67f,d 3.79h 
Viremia 28 4.66g 4.7g,a 3.96c,b 2.56h,d 
Viremia AUC 124.11g,d 127.53g,d 104.06c 72.991h,d 
 
1The infected individuals were separated in groups based on their response to infection as 1) early 2) late 
and 3) no response to infection.  
 
Significant differences between groups are represented with different superscripts in the same row as 
follows: a,b P < 0.05, c,d P < 0.01, e,f P < 0.001 and g,h P < 0.0001 or i,jP < 0.0001. 
 
2Units for ADG are kilograms of gain per day; units for IgG are sample-to-positive ratio; units for viremia 
are viral DNA copies per ml serum (log 10). 
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Table 4. Correlations between weight gain and viral load - Trial 2. 
 
 ADG 
0 to 7 
ADG 
0 to 14 
ADG 
0 to 21 
ADG 
0 to 28 
AUC 
0 to 7 
AUC 
0 to 14 
AUC 
0 to 21 
AUC 
0 to 28 
ADG 
0 to 7 
1.00 0.83 0.74 0.66 -0.01 -0.02 -0.03 -0.04 
ADG 
0 to 14 
0.83 1.00 0.88 0.82 -0.12 -0.12 -0.11 -0.12 
ADG 
0 to 21 
0.74 0.88 1.00 0.92 -0.17 -0.17 -0.18 -0.20 
ADG 
0 to 28 
0.66 0.82 0.92 1.00 -0.22a -0.24a -0.27a -0.29b 
AUC 
0 to 7 
-0.01 -0.12 -0.17 -0.22 1.00 0.96 0.84 0.78 
AUC 
0 to 14 
-0.02 -0.12 -0.17 -0.24 0.96 1.00 0.95 0.90 
AUC 
0 to 21 
-0.03 -0.11 -0.18 -0.27 0.84 0.95 1.00 0.99 
AUC 
0 to 28 
-0.04 -0.12 -0.20 -0.29 0.78 0.90 0.99 1.00 
 
a Indicates P < 0.05 and  b indicates P < 0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83 
FIGURES 
 
Figure 1. Log 10 of viral copy number for two crossbred lines - Trial 1. 
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Figure 2. Overlay plots of Minor Allelic Frequency vs. SNP Position  
for each chromosome - Trial 1 and 2. 
 
           SSC1                SSC2 
 
   
           SSC3             SSC4 
 
  
           SSC5              SSC6 
 
 
           SSC7             SSC8 
 
 85 
    
           SSC9            SSC10 
 
 
         SSC11            SSC12 
 
  
          SSC13            SSC14 
 
  
          SSC15                          SSC16 
 
 
 
 
 
 86 
 
 
          SSC17             SSC18 
 
 
          SSCX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 87 
Figure 3. Overlay plots of Hardy Weinberg Chi-Square Values vs. SNP Position  
for each chromosome - Trial 1 and 2. 
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Figure 4. IgM sample to positive ratios (S/P) during the experimental challenge of two 
crossbred lines - Trial 2. Large White x Landrace pigs are denoted W x R, while Duroc 
(Large White x Landrace) pigs are denoted D (W x R). 
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Figure 5. IgG sample to positive ratios (S/P) during the experimental challenge of  
two crossbred lines - Trial 2. Large White x Landrace pigs are denoted W x R, while 
Duroc (Large White x Landrace) pigs are denoted D (W x R). 
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Figure 6. Individual patterns of IgM response to an experimental PCV2 infection -  
Trial 21. 
 
 
 
1Infected individuals display different patterns of response to infection as: 1) early response- solid black; 
2) late response- solid grey; 3) no response- dashed black. 
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Figure 7. Least Square Means of IgM sample to positive ratios (S/P) profile during 
PCV2b experimental infection based on grouping by IgM response - Trial 2. 
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Figure 8. Log 10 of viral copy number for the two crossbred lines - Trial 2. Large White 
x Landrace pigs are denoted W x R, while Duroc (Large White x Landrace) pigs are 
denoted D (W x R). 
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Figure 9.  Genome wide associations between SNP genotypes and PCV2-specific IgM at 
d21 - Trial 21. 
 
 
 
 
 
1The X-axis represents the location of the SNPs from SSC1 to 18, SSCX and a group of SNPs (represented 
in grey) without a precise location. Y-axis represents the F value. Each dot represents the F value 
corresponding to the additive effect of a SNP. 
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Figure 10. Individual correlations between ADG and viremia AUC based on grouping by 
IgM response - Trial 2. Axes represent Z score values for ADG on the x axis and AUC 
PCV2 copy number on the y axis. 
 
 
 
Overall correlation: r = -0.29 (p < 0.01)  
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APPENDIX 
 
Appendix Ia. Genome wide associations between SNP genotypes and traits measured in 
Trial 1- additive effects. 
 
ADG d0 to d49 (t > 9.3 corresponds to a FDR < 0.3) 
 
ADG d14 to d49 (t > 19.0  corresponds to a FDR < .1) 
 
ADG d0 to d14 (t > 21.6 corresponds to a FDR < 0.11) 
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IgG d14 (t > 8.6 corresponds to a FDR < 0.4) 
 
IgG d49 (t > 17 corresponds to a FDR < 0.78 ) 
 
IgG Necropsy (t > 9.5 corresponds to a FDR < 0.4 ) 
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IgM d14 (t > 11.2 corresponds to a FDR < 0.2) 
 
IgM d49 (t > 13.1 corresponds to a FDR < 0.4) 
 
 
IgM Necropsy (t > 8.9 corresponds to a FDR < 0.7) 
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Viremia d49 (t > 8.7 corresponds to a FDR < 0.6) 
 
Viremia Necropsy (t > 9.2 corresponds to a FDR < 0.9) 
 
Viremia AUC (t > 5.9 corresponds to a FDR < 0.81) 
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Appendix Ib. Genome wide associations between SNP genotypes and traits measured in 
Trial 1- dominance effects. 
ADG d0 to d14 (t > 5.37 corresponds to a FDR < 0.9) 
 
ADG d14 to d49 (t > 13.7 corresponds to a FDR < 0.2) 
 
ADG d0 to d49 (t > 13.6 corresponds to a FDR < 0.3) 
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IgG d14 (t > 6.0 corresponds to a FDR < 0.7) 
 
IgG d49 (t > 13.2 corresponds to a FDR < 0.71) 
 
IgG Necropsy (t > 9.0 corresponds to a FDR < 0.6) 
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IgM d14 (t > 17.4 corresponds to a FDR < 0.1) 
 
IgM d49 (t > 6.3 corresponds to a FDR < 0.8) 
 
IgM Necropsy (t > 7.6 corresponds to a FDR < 0.5) 
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Viremia d49 (t > 9.9 corresponds to a FDR < 0.3) 
 
Viremia Necropsy (t > 13.9 corresponds to a FDR < 0.6) 
  
Viremia AUC (t > 6.0 corresponds to a FDR < 0.9) 
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Appendix IIa. Genome wide associations between SNP genotypes and traits measured in 
Trial 2- additive effects. 
ADG d0 to d7 (t > 10.0 corresponds to a FDR < 0.2) 
 
ADG d7 to d14 (t > 20.3 corresponds to a FDR < 0.45) 
 
ADG d14 to d21 (t > 26 corresponds to a FDR < 0.085) 
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ADG d21 to Necropsy (t > 11.5 corresponds to a FDR < 0.1) 
 
IgG d0 (t > 10.8 corresponds to a FDR < 0.3) 
 
IgG d7 (t > 5.9 corresponds to a FDR < 0.4) 
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IgG d14 (t > 6.8 corresponds to a FDR < 0.6) 
 
IgG d21 (t > 7.2 corresponds to a FDR < 0.6) 
 
IgG Necropsy (t > 7.1 corresponds to a FDR < 0.5) 
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IgM d0 (t > 9.3 corresponds to a FDR < 0.9) 
 
IgM d7 (t > 11.0 corresponds to a FDR < 0.4) 
 
IgM d14 (t > 15.2 corresponds to a FDR < 0.1) 
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IgM d21 (t > 6.2 corresponds to a FDR < 0.5) 
 
IgM Necropsy (t > 9.8 corresponds to a FDR < 0.2) 
 
Viremia d7 (t > 11.2 corresponds to a FDR < 0.7) 
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Viremia d21 (t > 8.8 corresponds to a FDR < 0.3) 
 
Viremia d14 (t > 5.8 corresponds to a FDR < 0.4) 
 
Viremia Necropsy (t > 8.5 corresponds to a FDR < 0.5) 
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Viremia AUC (t > 25.6 corresponds to a FDR < 0.1) 
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Appendix IIb. Genome wide associations between SNP genotypes and traits measured in 
Trial 2- dominance effects. 
ADG d0 to d7 (t > 5.5 corresponds to a FDR < 0.7) 
 
ADG d7 to d14 (t > 12.0 corresponds to a FDR < 0.999) 
 
 
ADG d14 to d21 (t > 9.4 corresponds to a FDR < 0.6) 
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ADG d21 to Necropsy (t > 5.0 corresponds to a FDR < 0.5) 
 
IgG d0 (t > 11.2 corresponds to a FDR < 0.3) 
 
IgG d7 (t > 7.6 corresponds to a FDR < 0.3) 
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IgG d14 (t > 5.6 corresponds to a FDR < 0.7) 
 
IgG d21 (t > 7.2 corresponds to a FDR < 0.7) 
 
IgG Necropsy (t > 7.0 corresponds to a FDR < 0.5) 
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IgM d0 (t > 11.4 corresponds to a FDR < 0.7) 
 
IgM d7 (t > 11.8 corresponds to a FDR < 0.3) 
 
IgM d14 (t > 13.3 corresponds to a FDR < 0.3) 
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IgM d21 (t > 5.9 corresponds to a FDR < 0.8) 
 
IgM Necropsy (t > 7.0 corresponds to a FDR < 0.4) 
 
Viremia d7 (t > 11.5 corresponds to a FDR < 0.9) 
 
 117 
 
Viremia d14 (t > 6.8 corresponds to a FDR < 0.6) 
 
Viremia d21 (t > 10.2 corresponds to a FDR < 0.2) 
 
Viremia Necropsy (t > 8.1 corresponds to a FDR < 0.9) 
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Viremia AUC (t > 10.5 corresponds to a FDR < 0.4) 
 
